;

House Publications

The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication

Bilingual view PDF


Tuesday, May 7, 2024 (No. 310)

Questions

Those questions not appearing in the list have been answered, withdrawn or made into orders for return.

Q-2487² — March 21, 2024 — — With regard to Health Canada's (HC) authorization of COVID-19 vaccines: (a) has HC received studies about theoretical risk of Vaccine-Associated Enhanced Disease (VAED), also referred to as Antibody-Dependent Enhancement (ADE), from the manufacturers of the COVID-19 vaccines; (b) if the answer to (a) is affirmative, (i) what were the outcome of the studies, (ii) which manufacturers and independent researchers are conducting these studies, (iii) what were the timelines to completion; (c) if the answer to (a) is negative, did HC, the Public Health Agency of Canada, or the National Advisory Committee identify a need for long-term studies to examine VAED, and, if not, why not; (d) has any federal health agency, department or other government entity been monitoring for VAED ADE post-COVID-19 injections; (e) if the answer to (d) is affirmative, (i) what is the data, (ii) what are the timelines, (iii) was this active or passive monitoring; (f) if the answer to (d) is negative, why not; and (g) has any federal health agency, department or other government entity been monitoring for the potential of vaccine-enhanced infectivity?

Q-2488² — March 21, 2024 — — With regard to the Framework for Cooperation on Countering Terrorism and Violent Extremism between Canada and India, signed by the current government: (a) is the framework still in effect; (b) has any information been shared between law enforcement or security agencies of Canada and India since June 18, 2023; and (c) was any information shared at any time between law enforcement or security agencies of Canada and India regarding Hardeep Singh Nijjar?

Q-2489² — April 4, 2024 — — With regard to phone lines paid for by the government, broken down by cellular line versus traditional landline, for each part of the question: (a) how many phone lines was the government paying for as of April 1, 2024; (b) how many of the phone lines are dormant; (c) how many of the phone lines are active but have not been used or have not had any activity in the last year; (d) how many of the phone lines are considered redundant; and (e) what was the total amount spent on phone lines during the 2023 calendar year or the 2023-24 fiscal year, if known, broken down by service provider?

Q-2490² — April 4, 2024 — — With regard to Canada Post: (a) what was the total amount spent on fuel in the last year; (b) what is the breakdown of (a) by gasoline versus diesel; (c) what is the estimated number of litres of (i) gasoline, (ii) diesel fuel, purchased in the last year; (d) how many vehicles does Canada Post currently own; (e) what is the breakdown of vehicles owned by (i) diesel fueled, (ii) gasoline fueled, (iii) hybrid, (iv) electric; (f) what is the estimated number of kilometers driven by Canada Post vehicles last year; and (g) what is the breakdown of (a) through (f) by province or territory?

Q-2491² — April 4, 2024 — — With regard to the Housing Accelerator Fund, since September 1, 2023: (a) how many applications for federal funding were rejected or unsuccessful, broken down by (i) province or territory, (ii) municipality; and (b) what is the projected number of residences that could have been constructed if funding was provided?

Q-2492² — April 4, 2024 — — With regard to federal procurement: (a) how many cases of suspected invoicing fraud by Information Technology (IT) subcontractors have been submitted to the RCMP for investigation since January 2024; and (b) which departments are involved?

Q-2493² — April 4, 2024 — — With regard to revoked or suspended security clearances of contractors since January 2024: what are the details of all revoked contracts, including the (i) department, (ii) vendor, (iii) value, (iv) description of the goods and services, (v) date the contract was signed, (vi) start and end dates?

Q-2494² — April 4, 2024 — — With regard to contracts awarded through a non-competitive process since March 2020: what is the total value of contracts awarded to (i) GC Strategies, (ii) Dalian Enterprises Inc., (iii) Amazon Web Services Inc., (iv) Microsoft Canada Inc., (v) TEKsystems Inc., (vi) Donna Cona Inc., (vii) MGIS Inc., (viii) 49 Solutions, (ix) Makwa Resourcing Inc., (x) TPG Technology Consulting Ltd., (xi) Advanced Chippewa Technologies Inc.?

Q-2495² — April 4, 2024 — — With regard to federal spending in the electoral district of Rimouski-Neigette—Témiscouata—Les Basques, broken down by fiscal year since 2018–19, inclusively: (a) what is the total amount for each fiscal year; (b) what is the detailed breakdown of the amounts in (a) by department, Crown corporation, agency or organization; and (c) what grants and contributions were made, broken down by funding source?

Q-2496² — April 4, 2024 — — With regard to Transport Canada (TC) and the Canadian Transportation Agency data for air travel from January 1, 2018, to December 31, 2023: (a) how many in-flight medical events occurred in Canadian airspace; (b) what is the breakdown of (a) by (i) flight type (i.e. commercial, private, freight, charter, other), (ii) airline, (iii) affected person type (i.e. pilots, other flight crew and passengers), (iv) year, (v) month; (c) how many in-flight medical events occurred on airplanes registered in Canada outside the Canadian airspace; (d) what is the breakdown of (c) by (i) flight type (i.e. commercial, private, freight, charter, other), (ii) airline, (iii) affected person type (i.e. pilots, other flight crew and passengers); (e) how many flights and miles were flown in Canadian airspace; (f) how many emergency landings occurred in the Canadian airspace; (g) what is the breakdown of (f) by (i) reason, (ii) airline, (iii) airplane model; (h) how many active Canadian commercial pilots, flight attendants, and air traffic controllers died; (i) what medical screening changes occurred with respect to pilots, flight attendants, and air traffic controllers (e.g. medical certification requirements changes); (j) for each medical screening change, (i) what it the reason, (ii) what is the date of the change, (iii) who are the persons and decision bodies who approved the change; (k) how many pilots, flight attendants, and air traffic controllers claimed disability; (l) how many pilots, flight attendants, and air traffic controllers applied for medical leave; (m) how many pilots underwent their annual medical examination; (n) how many pilots failed their annual medical examinations; (o) how many active pilot licenses existed; (p) how many pilots, flight attendants, and air traffic controllers lost their employment or were placed on an unpaid leave as a result of refusal to take the COVID-19 vaccines or refusal to inform their employer about their COVID-19 vaccination status; (q) how many pilots lost their license for medical reasons; (r) does TC keep data relating to the numbers of Category 1-3 medical certificates that are (i) held, (ii) temporarily suspended, (iii) permanently suspended for non-compliance with COVID-19 vaccine policy; and (s) if the answers to (r)(i), (r)(ii) or (r)(iii) are affirmative, what is the data?

Q-2497² — April 4, 2024 — — With regard to Environment and Climate Change Canada’s funding of the barn swallow nesting structure project in Prince Edward Point: (a) what was the cost of the project, in total, and broken down by item and type of expense; and (b) what are the details of all contracts related to the project, including, for each, the (i) amount, (ii) vendor, (iii) date and duration, (iv) description of the goods or services provided, (v) manner in which the contract was awarded (i.e. sole-sourced or competitive bid)?

Q-2498^1-2 — April 4, 2024 — — With regard to the completion date on the Gordie Howe International Bridge project being delayed until September 2025: (a) was the delay related to disputes with Valard Construction; (b) to which of the four major associated construction projects are the additional $700 million assigned, and which of these projects is expected to result in more claims; (c) will the $700 million cover the overrun costs to the subcontractors until the end of 2022; (d) what additional funds will be allocated for work order charges from 2023, 2024 and 2025 until the end of the project; and (e) if there will be no additional funds allocated, will the government confirm there will be no more contractors' claims for the remainder of the project?

Q-2499^1-2 — April 4, 2024 — — With regard to the Gordie Howe International Bridge project: (a) what are the estimated costs to taxpayers associated with the new completion date; and (b) will the cost overruns, those identified and the others yet to be determined, lengthen the time it takes for Canadian taxpayers to be reimbursed through the collection of tolls, will the toll charges be increased to cover the additional costs, or both?

Q-2500² — April 4, 2024 — — With regard to the Canada Post building located at 180 Victoria Street, Salaberry-de-Valleyfield: (a) what are the annual expenses related to the operation of the post office and the sorting facility; (b) what investments are planned between now and 2030 at this building and for the operations that take place there; and (c) what is the estimated market value of the building and the land?

Q-2501² — April 4, 2024 — — With regard to government funding of non-governmental organizations or groups, from November 4, 2015, to present: (a) how much money has the government allocated to (i) Green Economy Canada, (ii) Alberta EcoTrust, (iii) Corporate Knights, (iv) Echo Foundation, (v) Eco Canada, (vi) Ivey Foundation, (vii) Resilient LLP, (viii) Canadian Climate Institute, (ix) Ecofiscal Commission; (b) for each entity in (a), what are the details, including the (i) department, agency or other government entity, (ii) date of the funding, (iii) amount and deliverables expected; (c) of the allocations in (a), which ones were (i) sole-sourced, (ii) awarded through a competitive bidding process; (d) of the allocations in (c)(ii), what was the (i) duration of the competition, (ii) number of organizations that submitted bids for the required deliverables; and (e) what programs from each organization in (a) received government funding, broken down by year and deliverables expected?

Q-2502² — April 8, 2024 — — With regard to the government’s approach to the visit of Nishan Duraiappah, Chief of Peel Regional Police, to Sri Lanka: (a) did the Government of Canada or any Canadian public entity assist in the visit, and, if so, who assisted and what form of assistance was provided; (b) did any Canadian government representative attend any meetings along with Chief Duraiappah, and, if so, what departments or agencies were in attendance; and (c) does the Government of Canada support or facilitate police exchanges or police cooperation between forces in Canada and Sri Lanka?

Q-2503² — April 8, 2024 — — With regard to the social media post by Veterans Affairs Canada (VAC) on March 29, 2024, about a "March holiday season": (a) who wrote the post; (b) what is the process for approving VAC tweets, including which official in the minister's office reviewed the content before being posted and was the process followed in this case; (c) who decided to replace the term "Easter weekend" with "March holiday season"; (d) will VAC be adjusting its March holiday season greeting in years where Easter falls in April; and (e) has any VAC employee faced any disciplinary action as a result of the fallout from this post, and, if so, what measures were taken?

Q-2504² — April 8, 2024 — — With regard to the Canada Disability Benefit Act and the reference to regulations to be made under the Act in section 11: (a) will the regulatory framework be in place by June 2024, as stipulated under the Act; (b) how much progress has been made on the regulatory framework to date; (c) when does the government anticipate that benefits will start being paid out to eligible persons with disabilities; (d) what will be the eligibility criteria to qualify for the benefit; (e) what will the dollar amount of the benefit be to the average Canadian with a disability; (f) what metrics and standards will be used to determine the benefit amount; (g) what is the anticipated financial cost of the program; (h) how will the government determine whether the benefit has achieved the Act's stated goal of lifting Canadians with disabilities out of 'poverty'; (i) will the government implement one of the three scenarios laid out in the Parliamentary Budget Officer's November 2023 report entitled "The Canada Disability Benefit: Model and Scenarios", and, if so, which one; and (j) which stakeholders and interest groups are being consulted during the regulatory process?

Q-2505² — April 8, 2024 — — With regard to Old Age Security (OAS): (a) how many OAS payment recipients were not residents of Canada for tax purposes in the 2023 tax year; (b) what was the total amount paid out in OAS payments to the recipients in (a); and (c) for OAS program recipients outside of Canada, what is the breakdown by country of the aggregate number of recipients, and the total amount paid for each of the tax years 2022 and 2023?

Q-2506² — April 8, 2024 — — With regard to Health Canada's MedEffect website: (a) is the process outlined in the guide entitled "Adverse Reaction Reporting and Health Product Safety Information: Guide for Health Professionals", the protocol that healthcare providers have to follow since December 1, 2020, to report COVID-19 vaccine adverse reactions; (b) if the answer to (a) is negative, (i) when did the process change, (ii) which official in what department initiated the process change, (iii) what was the reason for the change; (c) since December 2020, what has been the new reporting protocol guidance to report COVID-19 vaccine adverse reactions; (d) how were health professionals informed of the change in (c); and (e) what were the substantive differences from the protocol for reporting a vaccine adverse reaction prior to December 2020 and the new protocol outlined in (c)?

Q-2507² — April 8, 2024 — — With regard to the government's carbon tax rebates owed to businesses since the implementation of the federal carbon pricing program in 2019: (a) what is the total amount still owed by the federal government in carbon tax rebates to businesses, broken down by (i) small businesses, (ii) medium-sized businesses; (b) what are the specific amounts owed to businesses in each province and territory, broken down by (i) small businesses, (ii) medium-sized businesses; (c) what measures is the government taking to ensure that outstanding carbon tax rebates are processed and delivered to businesses in a timely manner; and (d) how many businesses, broken down by size (i.e., small, medium) and by province and territory, have not yet received their carbon tax rebates?

Q-2508² — April 8, 2024 — — With regard to the Canada Revenue Agency: as of April 8, 2024, how many T3 filing forms were completed by bare trusts, and how many taxpayers have filed T3 forms relating to bare trusts?

Q-2509² — April 9, 2024 — — With regard to the Public Service Pension Plan, as of January 1, 2024: (a) what is the number of (i) public sector employees, (ii) retirees, (iii) former employees, in Group 1 of the Public Service Pension Plan; (b) what is the number of (i) public sector employees, (ii) retirees, (iii) former employees, in Group 2 of the Public Service Pension Plan; (c) what is the projected surplus in the Public Service Pension Plan; (d) what percentage of the plan is funded; and (e) what plans, if any, does the government have to distribute funds over the permissible surplus level?

Q-2510² — April 9, 2024 — — With regard to Environment and Climate Change Canada (ECCC): (a) what is the total amount of grants and contributions provided by ECCC to (i) not-for-profit organizations or charities, (ii) academia, (iii) international non-governmental organizations, broken down by year since 2019; and (b) what are the details of each grant or contribution in (a), including, for each, the (i) date, (ii) amount, (iii) recipient, (iv) purpose of the funding?

Q-2511² — April 9, 2024 — — With regard to the Deficit Reduction Action Plan, between January 1, 2011, and January 1, 2016: how many jobs were cut or eliminated from the federal public service, broken down by (i) province and territory, (ii) department and agency, (iii) job type?

Q-2512² — April 9, 2024 — — With regard to federal investments in Canada’s telecommunications sector, since January 1, 2006: how much federal funding has been provided to (i) Rogers Communications Inc., (ii) BCE Inc., (iii) Telus Mobility, broken down by company, year and type of funding?

Q-2513² — April 9, 2024 — — With regard to bonuses paid out at government departments or agencies in the 2023-24 fiscal year, broken down by department or agency: (a) what was the total amount paid out in bonuses; (b) how many and what percentage of officials (i) at or above the executive (EX) level or equivalent, (ii) below the EX level or equivalent, received bonuses; and (c) of the amount paid out in bonuses, how much went to officials (i) at or above the EX level or equivalent, (ii) below the EX level or equivalent?

Q-2514² — April 9, 2024 — — With regard to bonuses paid out at Crown corporations in the 2023-24 fiscal year, broken down by Crown corporation: (a) what was the total amount paid out in bonuses; (b) how many and what percentage of officials (i) at or above the executive (EX) level or equivalent, (ii) below the EX level or equivalent, received bonuses; and (c) of the amount paid out in bonuses, how much went to officials (i) at or above the EX level or equivalent, (ii) below the EX level or equivalent?

Q-2515² — April 9, 2024 — — With regard to the Canada Revenue Agency, broken down by month since January 2022: (a) how many requests for technical assistance have been received by (i) income tax service providers, (ii) the general public; and (b) of the requests in (a), what is the breakdown by the (i) type of tax filer, (ii) type of issue requiring assistance, (iii) forms, (iv) tax measures involved?

Q-2516² — April 9, 2024 — — With regard to reports, studies, assessments, and evaluations (hereinafter referred to as "deliverables") prepared for the government, including any department, agency, Crown corporation or other government entity, by McKinsey & Company since December 1, 2020: what are the details for each deliverable, including the (i) date that the deliverable was finished, (ii) title, (iii) summary of recommendations, (iv) file number, (v) website where the deliverable is available online, if applicable, (vi) value of the contract related to the deliverable?

Q-2517² — April 9, 2024 — — With regard to the impact of the carbon tax on school boards, divisions, and educational institutions across Canada, since 2019: (a) how many school boards, divisions, and educational institutions have been consulted or met regarding the impact of the carbon tax on their financial situation, and what are the details of each such consultation, including (i) the date, (ii) who did the consultation, (iii) who was consulted, (iv) the location, (v) the type of consultation; (b) of the 10% of carbon tax revenues earmarked for funding programs aimed at reducing emissions, how much has been allocated to school boards, divisions, and educational institutions, broken down by (i) province and territory, (ii) year, (iii) recipient, (iv) project description; (c) what is the total amount of carbon price revenues collected from school boards, divisions, and educational institutions since 2019, broken down by (i) province and territory, (ii) year; (d) what is the government's estimate of the annual amount of carbon tax collected on gasoline or fuel purchased for school buses; (e) if the government does not have any estimate for (d), why has this not been studied; and (f) has the government conducted any analyses to determine the total financial net cost of the carbon tax on school boards, divisions, and educational institutions, and, if so, what are the details, including, for each, (i) the name of the study, (ii) who conducted the study, (iii) the date, (iv) the findings?

Q-2518² — April 9, 2024 — — With regard to reports, studies, assessments, and evaluations (hereinafter referred to as "deliverables") prepared for the government, including any department, agency, Crown corporation or other government entity, by Deloitte since December 1, 2020: what are the details for each deliverable, including the (i) date that the deliverable was finished, (ii) title, (iii) summary of recommendations, (iv) file number, (v) website where the deliverable is available online, if applicable, (vi) value of the contract related to the deliverable?

Q-2519² — April 9, 2024 — — With regard to reports, studies, assessments, and evaluations (hereinafter referred to as "deliverables") prepared for the government, including any department, agency, Crown corporation or other government entity, by PricewaterhouseCoopers since December 1, 2020: what are the details for each deliverable, including the (i) date that the deliverable was finished, (ii) title, (iii) summary of recommendations, (iv) file number, (v) website where the deliverable is available online, if applicable, (vi) value of the contract related to the deliverable?

Q-2520² — April 9, 2024 — — With regard to reports, studies, assessments, and evaluations (hereinafter referred to as "deliverables") prepared for the government, including any department, agency, Crown corporation or other government entity, by Accenture since December 1, 2020: what are the details for each deliverable, including the (i) date that the deliverable was finished, (ii) title, (iii) summary of recommendations, (iv) file number, (v) website where the deliverable is available online, if applicable, (vi) value of the contract related to the deliverable?

Q-2521² — April 9, 2024 — — With regard to reports, studies, assessments, and evaluations (hereinafter referred to as "deliverables") prepared for the government, including any department, agency, Crown corporation or other government entity, by KPMG since December 1, 2020: what are the details for each deliverable, including the (i) date that the deliverable was finished, (ii) title, (iii) summary of recommendations, (iv) file number, (v) website where the deliverable is available on line, if applicable, (vi) value of the contract related to the deliverable?

Q-2522² — April 9, 2024 — — With regard to funding allocated to Pathways to Recovery's Safer Supply Ottawa Program through Health Canada's Substance Use and Addictions Program (SUAP), since 2016: (a) what specific measures, if any, were implemented to ensure that companies owned or operated by members of Pathway's board of directors did not financially benefit from the funding; (b) prior to receiving the SUAP grants, did Pathways disclose any conflicts of interest to the government, including whether or not any of their board of directors would profit from funding provided; (c) do any of the terms within the funding agreements include prohibitions on conflicts of interests and personal profit from the grants, and, if so, which agreements include such terms and what are their summary; (d) what are the details of all funding provided to Pathways, broken down by the (i) date, (ii) amount, (iii) project description; and (e) what specific safeguards, if any, are in place to ensure that substances provided by Pathways do not end up trafficked by drug dealers?

Q-2523² — April 9, 2024 — — With regard to the government's response to the April 1, 2024, “Axe the Tax” rallies across Canada: (a) did the Minister of Public Safety issue any directives or advice to the RCMP or other police agencies in relation to the rallies, and, if so, what are the details, including the directive or advice; and (b) did the RCMP issue any directives or advice to RCMP officers assigned to the rallies and, if so, for each instance, (i) who provided the directive or advice, (ii) what was the directive or advice, (iii) what location or locations was the directive or advice intended for?

Q-2524² — April 9, 2024 — — With regard to the communities which comprise the federal electoral district of Courtenay—Alberni, since fiscal year 2005-06: (a) what are the federal infrastructure investments, including direct transfers to municipalities and First Nations, for the communities of (i) Tofino, (ii) Ucluelet, (iii) Port Alberni, (iv) Parksville, (v) Qualicum Beach, (vi) Cumberland, (vii) Courtenay, (viii) Deep Bay, (ix) Dashwood, (x) Royston, (xi) French Creek, (xii) Errington, (xiii) Coombs, (xiv) Nanoose Bay, (xv) Cherry Creek, (xvi) China Creek, (xvii) Bamfield, (xviii) Beaver Creek, (xix) Beaufort Range, (xx) Millstream, (xxi) Mt. Washington Ski Resort, broken down by fiscal year, total expenditure, and project; (b) what are the federal infrastructure investments transferred to the regional districts of (i) Comox Valley Regional District, (ii) Nanaimo Regional District, (iii) Alberni-Clayoquot Regional District, (iv) Powell River Regional District, broken down by fiscal year, total expenditure, and project; (c) what are the federal infrastructure investments transferred to the Island Trusts of (i) Hornby Island, (ii) Denman Island, (iii) Lasquetti Island, broken down by fiscal year, and total expenditure; (d) what are the federal infrastructure investments transferred to the (i) Ahousaht First Nation, (ii) Hesquiaht First Nation, (iii) Huu-ay-aht First Nation, (iv) Hupacasath First Nation, (v) Tla-o-qui-aht First Nations, (vi) Toquaht First Nation, (vii) Tseshaht First Nation, (viii) Uchucklesaht First Nation, (ix) Ucluelet First Nation, (x) K'omoks First Nation, broken down by fiscal year, total expenditure, and project; (e) what is the infrastructure funding of Pacific Rim National Park, broken down by fiscal year, total expenditure, and project; (f) what is the funding of highways, including, but not limited to, (i) Highway 4, (ii) Highway 19, (iii) Highway 19a, (iv) Bamfield Road, broken down by fiscal year, total expenditure, and project; and (g) what other infrastructure investments are provided through the funding of national parks, highways, the Building Canada Fund, Infrastructure Canada, the Gas Tax Fund, Small Crafts and Harbours, BC Ferries, etc., broken down by fiscal year, total expenditure, and project?

Q-2525² — April 9, 2024 — — With regard to Agriculture and Agri-Food Canada’s AgriCompetitiveness Program, broken down by year for each of the last ten fiscal years: (a) which organizations applied for funding through the program; and (b) how much did each organization in (a) (i) request, (ii) receive, in funding?

Q-2526² — April 10, 2024 — — With regard to healthcare in Canada: (a) what is specifically included under universal health services; (b) has the scope of services included under universal health services changed since first implemented and, if so, (i) what are the changes, (ii) on what dates did these changes take place; (c) what are the specific services that are (i) funded publicly, (ii) not fully publicly funded; (d) what was the annual total health spending in Canada, broken down by year from 2010 to present; (e) what was the private total health spending in Canada since 2010 to present; (f) what, if any, publicly insured services are being offered for out-of-pocket pay, and, if relevant, what is the annual spending since 2010; (g) what was the annual per capita spending on health since 2010, and how does per capita spending compare to that of Organisation for Economic Co-operation and Development (OECD) countries; (h) what was the private annual per capita spending on health since 2010; (i) what was the investment in homecare since 2010, and, for each investment, (i) how many more people were served, (ii) what was the average wait time from approval to service delivery, (iii) has the wait time from approval to service delivery changed; (j) what, if any, mechanisms have existed to hold provinces and territories accountable on how they spend the health transfer, and, if relevant, what is (i) the accountability mechanism, (ii) the date; (k) for each province and territory, what is the annual funding compared to the age-adjusted population growth since 2010; (l) for each province and territory, what is specifically included under universal health services; (m) for each province and territory, has the scope of services changed since universal health services were first implemented, and, if so, what are (i) the changes, (ii) the dates of the changes; (n) for each province and territory, what are the specific services that are (i) funded publicly, (ii) not fully publicly funded; (o) for each province and territory, what (i) is the percentage increase in healthcare service costs since the last health transfer, (ii) is the new negotiated health transfer, (iii) new services will the transfer buy for Canadians; (p) where does Canada rank with respect to amenable mortality among comparator countries, and (i) where have there been improvements, (ii) where specifically has there been a lack of improvement; (q) what does Canada spend on pharmaceuticals, and how does Canada rank among the OECD; (r) what are all of the pan-Canadian health benchmarks, and what is the target for each benchmark; (s) for each benchmark, what is the percentage of patients receiving care within each of the pan-Canadian benchmarks, broken down by province and territory; (t) what is the percentage of patients receiving care within the benchmarks for (i) cataract removal, (ii) hip fracture repair, (iii) hip replacement, (iv) knee replacement, broken down by province and territory; (u) how does Canada rank with respect to service wait times for comparator countries, specifically to (i) see a general practitioner, (ii) see a specialist, (iii) be treated in an emergency department, (iv) receive advanced diagnostics, (v) receive elected surgical care; (v) what is the average wait time to (i) see a general practitioner, (ii) see a specialist, (iii) be treated in an emergency department, (iv) receive advanced diagnostics, (v) receive elected surgical care, in each province and territory; (w) how many people left an emergency department in 2022-23 without ever having been seen, broken down by province and territory; (x) what is the health and social services sector vacancy rate in each province and territory; (y) what is the physician supply gap in each province and territory and how does Canada rank against comparator countries; (z) in each province and territory, (i) what is the vacancy rate for nurses, (ii) what discipline has the highest vacancy rate; (aa) broken down by province and territory, what percentage of Canadians lack a primary care provider; (bb) how does Canada rank on inequality in healthcare by income compared to other countries; (cc) what groups of Canadians have difficulty accessing primary care, and, for each group identified, how (i) is access to a general practitioner, (ii) is prescription use, (iii) is access to a specialist, (iv) are diagnostics, (v) is treatment, (vi) is morbidity, (vii) is mortality, impacted; (dd) in each province and territory, what percentage of cost is covered for prescription drugs outside (i) the hospital, (ii) homecare, (iii) non-physician mental health care; (ee) what percentage of income do Canadians in the lowest income quintile spend on their healthcare; (ff) what percentage of income do Canadians in the highest income quintile spend on their healthcare; (gg) broken down by province and territory, (i) how many more people were served with respect to long-term care since 2010 by each federal health transfer, (ii) what was the average wait time from approval to service delivery, (iii) has the wait time from approval to service delivery changed; (hh) broken down by province and territory, what percentage of hospital-bed days is designated to those awaiting long-term care; (ii) how does Canada rank with respect to comparator countries on (i) health outcome measures, (ii) patient-reported experience; (jj) what specific data is collected at the federal level on medical errors, including, but not limited to, (i) patient harm, (ii) a foreign body left in after a procedure, (iii) obstetric trauma, (iv) postoperative pulmonary embolism after a hip replacement, (v) postoperative pulmonary embolism after a knee replacement, and how does this data compare internationally; (kk) what specific data is collected at the provincial and territorial level on (i) medical errors, (ii) patient harm; (ll) how does Canada rank with respect to comparator countries on (i) dental coverage, (ii) non-physician mental health care, (iii) vision?

Q-2527² — April 10, 2024 — — With regard to women’s health in Canada and clinical research funded by the Canadian Institutes of Health Research (CIHR): (a) how much did the government invest in women’s health annually, from 2010 to present, and specifically, for the same time period, how much was invested in (i) aging, (ii) cardiovascular conditions, (iii) neurological conditions, and how did these investments compare to that of the United States; (b) how much did the CIHR invest in women’s health annually, from 2010 to present, and specifically, for the same time period, how much was invested in (i) aging, (ii) cardiovascular conditions, (iii) neurological conditions, and how did these investments compare to that of the National Institutes of Health (NIH); (c) broken down by all common female-specific conditions, including, but not limited to, endometriosis, fibroid tumours, pelvic inflammatory disease, and polycystic ovary syndrome, (i) what are the number of women impacted, (ii) what is the cost to the healthcare system, (iii) what are the effective diagnostics, if any, (iv) what are the effective treatments, if any, (v) is the condition under-researched, (vi) what is the annual investment since 2010, (vii) how does investment compare to that of the United States, (viii) what is the annual investment by CIHR since 2010, (ix) how does investment compare to that of the NIH; (d) what annual investment has the government made since 2010 in (i) fertility, (ii) pregnancy, (iii) maternal health, (iv) reducing maternal morbidity and mortality, (v) breastfeeding, and how does investment compare to that of the United States; (e) what annual investment has the CIHR made since 2010 in (i) fertility, (ii) pregnancy, (iii) maternal health, (iv) reducing maternal morbidity and mortality, (v) breastfeeding, and how does investment compare to that of the NIH; (f) broken down by all specific female cancers including, but not limited to, cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, (i) what is the number of women impacted, (ii) what is the cost to the healthcare system, (iii) what are the effective diagnostics, if any, (iv) what are the effective treatments, if any, (v) what is the average cancer stage at diagnosis, (vi) what is the annual investment by the government since 2010, (vii) how does investment compare to that of the United States, (viii) what is the annual investment by the CIHR since 2010, (ix) how does the investment compare with that of the NIH; (g) broken down by all specific conditions that disproportionately affect women including, but not limited to, autoimmune diseases, chronic pain, Alzheimer’s disease, osteoporosis, and specific cancers, (i) what is the number of women affected, (ii) what is the cost to the health care system, (iii) what is the annual investment by the government since 2010, (iv) how does the investment compare to that of the United States, (v) what is the investment in research by the CIHR annually since 2010, (vi) how does the investment compare to that of the NIH; (h) what percentage of CIHR’s budget is invested in the gender and health institute, and how does this percentage compare to each of the remaining institutes; (i) does CIHR have a policy regarding the sex of animals used in pre-clinical research, and, if so, what are the details of the policy, including the date it came into effect; (j) does all CIHR-supported pre-clinical research require the use of female and male animals; (k) what percentage of CIHR’s pre-clinical research uses female animals, and how is that percentage measured; (l) what percentage of CIHR’s pre-clinical research reports on the sex of animal subjects, and how is it measured; (m) is it mandated that all CIHR-supported clinical research include women, and, if so, what (i) is the date of the mandate, (ii) is the policy, (iii) are the exceptions, (iv) are any requirements for analysis to include sex, gender, and intersectionality, (v) are any requirements for reporting on sex, gender, and intersectionality; (n) how specifically does CIHR track whether clinical research includes women, what are all questions on grant applications, and what questions and formulae are used to calculate the percentage of CIHR-supported clinical research involving women; (o) what percentage of CIHR-supported clinical research involves women; (p) what percentage of CIHR-funded research examines (i) sex, (ii) gender, (iii) intersectionality, and how are these measured; (q) what specific policies has CIHR put in place to ensure women of all ages and backgrounds are included in clinical research populations; (r) does CIHR provide support for research specifically focused on populations of women historically (i) under-represented, (ii) under-researched, (iii) under-reported, in clinical research, and, if so, what specific investment is made for each?

Q-2528² — April 10, 2024 — — With regard to the Defence Policy Update and the statement that “The government is projecting our defence spending to GDP ratio to reach 1.76% in 2029-30”: (a) what is the projected defence budget broken down by fiscal year from 2023-24 to 2029-30; (b) how much of that is allocated from the Defence Policy Update as a dollar value; (c) what is the projected GDP, broken down by fiscal year from 2023-24 to 2029-30; and (d) what is the projected defence spending to GDP ratio broken down by fiscal year from 2023-24 to 2029-30?

Q-2529² — April 10, 2024 — — With regard to government advertising during or connected to the Super Bowl, including the pre- and post-game broadcasts, on February 11, 2024: (a) what was the total amount spent on advertising; and (b) what is the breakdown of the spending by each advertisement, including a description of the contents, and by media outlet, along with when the advertisement ran (pre-game, during the game, etc.)?

Q-2530² — April 10, 2024 — — With regard to government grant programs which are or have been administered by external parties or vendors since 2016: what are the details of all such programs, including, for each, the (i) name of the program, (ii) description or purpose of the program, (iii) amount of funding provided through the grants, (iv) number of grant recipients, (v) name of the external party or vendor that administered the program, (vi) amount paid to the external party or vendor for administering the program, (vii) reason the government outsourced the administration of the program?

Q-2531² — April 10, 2024 — — With regard to the Housing Accelerator Fund: (a) what is the total amount of funding allocated in Ontario, broken down by each municipality; and (b) what is the breakdown of (a), by type of housing funded?

Q-2532² — April 11, 2024 — — With regard to the government's response to Order Paper Question Q-2055, tabled in the House of Commons on January 29, 2024, and the table provided in Appendix A on pages 42-51, broken down by the criteria previously provided: (a) how many of those individuals are currently in Canada on valid permits; (b) how many of those individuals are currently in Canada but do not have valid permits or have expired permits; and (c) how many of those individuals are no longer in Canada?

Q-2533² — April 11, 2024 — — With regard to the government's response to Order Paper Question Q-2232, tabled in the House of Commons on March 18, 2024: (a) for the 410 individuals in the Canada Border Services Agency’s response to part (e)(i), what are the specific offences that have deemed them inadmissible pursuant to s. 36(1)(a) or s. 36(2)(a) of the Immigration and Refugee Protection Act, for having been convicted in Canada of a Criminal Code offence; and (b) for the 236 individuals in the Canada Border Services Agency’s response to part (e)(ii), what are the specific (i) offences that have deemed them inadmissible pursuant to s. 36(1)(b) or s. 36(2)(b) of the Immigration and Refugee Protection Act, for having been convicted in their country of origin of an equivalent charge to a Criminal Code offence, (ii) countries of origin where the convictions occurred?

Q-2534² — April 11, 2024 — — With regard to Immigration, Refugees and Citizenship Canada (IRCC) and the Settlement Program, the Resettlement Assistance Program, the Interim Housing Assistance Program, the International Migration Capacity Building Program, and the Francophone Immigration Support Program, for the fiscal years 2015-16 to 2023-24, broken down by program and by province and territory: (a) what organizations applied for grants, contributions or loans; (b) how much did they apply for on an annual basis; (c) how much did they receive on an annual basis; (d) how much of their funding did IRCC allocate to administrative costs on an annual basis; and (e) what were the actual administrative costs on an annual basis?

Q-2535² — April 11, 2024 — — With regard to the government’s online estimators: (a) what were the costs associated with developing and implementing the AgriStability estimator, in total and broken down by type of expense; (b) what are the details of all contracts signed by the government related to (a), including, for each, the (i) date, (ii) vendor, (iii) value, (iv) description of goods or services; (c) what were the costs associated with developing and implementing the Canada Carbon Rebate estimator, in total and broken down by type of expense; and (d) what are the details of all contracts signed by the government related to (c), including, for each, the (i) date, (ii) vendor, (iii) value, (iv) description of goods or services?

Q-2536² — April 11, 2024 — — With regard to the government’s response to the International Civil Aviation Organization (ICAO) giving Canada a score of 64 out of 100 in a recent assessment: (a) what is the government’s explanation for the decrease in Canada’s score from 95 in 2005 to the latest score of 64; (b) on what date did Transport Canada receive the ICAO report; (c) what shortcomings were identified in the report; (d) what specific actions, if any, has the government taken to address each identified shortcoming; and (e) for each shortcoming in (c), by what date will each be brought up to standard?

Q-2537² — April 11, 2024 — — With regard to the revocation of government security clearances between January 1, 2023, and April 11, 2024: (a) how many individuals have had their security clearances revoked for cause (and not as a result of retirement or resignation); (b) of the revocations in (a), how many were due to the individual spying or otherwise acting on behalf of a foreign government; and (c) what is the breakdown of (a) and (b) by department, agency, Crown corporation, or other government entity?

Q-2538² — April 11, 2024 — — With regard to the revocation of government security clearances for ministerial exempt staff, including those from the Office of the Prime Minister, between January 1, 2016, and April 11, 2024: (a) how many individuals have had their security clearances revoked for cause (and not as a result of retirement or resignation); and (b) what is the breakdown of (a) by (i) year, (ii) minister whom they were working for at the time of revocation, (iii) reason for revocation?

Q-2539² — April 11, 2024 — — With regard to the Public Health Agency of Canada's procurement of ventilators from Canadian Emergency Ventilators Inc. in April 2020, and the subsequent sale of many of these ventilators as commodity code "9500 - Scrap metal" through the GC Surplus auction: (a) why were the ventilators classified and sold as scrap metal; (b) did the government offer these ventilators to the (i) provincial health authorities, (ii) National Emergency Strategic Stockpile, (iii) Department of National Defence, (iv) International Development section of Global Affairs Canada; (c) for each entity in (b) that received an offer, what reason was received by the government for the entity not accepting the ventilators; (d) for each entity in (b) that did not receive an offer, why did the government not offer the ventilators to them; (e) for the ventilators that have been disposed of to date, through either GC Surplus or other means, who was the recipient of the ventilators, what quantity did each recipient receive, and how much payment did the government receive; (f) have any of these ventilators ended up in private or for-profit health care entities, either in Canada or abroad, and, if so, what are the details; and (g) if the government does not know the answer to (f), why does the government not have that information?

Q-2540² — April 11, 2024 — — With regard to the First Home Savings Account (FHSA): (a) how many accounts are currently active; (b) what is the total cumulative amount held in all accounts; (c) what is the average and median account balance; (d) how many accounts have a balance of over (i) $1,000, (ii) $5,000, (iii) $10,000, (iv) $20,000, in them; and (e) what is the breakdown of the number of FHSA accounts by the owner's income bracket?

Q-2541² — April 11, 2024 — — With regard to the granting of government security clearances between January 1, 2023, and April 1, 2024: (a) how many individuals (i) applied for, (ii) were denied (not as a result of retirement or resignation), security clearances; (b) of the denials in (a), how many were due to the individual spying or otherwise acting on behalf of a foreign government; and (c) what is the breakdown of (a) and (b) by department, agency, Crown corporation, or other government entity and level of clearance applied (secret or top secret)?

Q-2542² — April 11, 2024 — — With regard to the Canada Digital Adoption Program: (a) how many of the 29,532 businesses which applied to the Boost Your Business Technology Stream were successful and received funding; (b) what was the total amount of funding given to businesses through the Boost Your Business Technology Stream; (c) what is the breakdown of the $13 million provided in the contribution agreement with Magnet for project implementation and administrative costs; (d) what are the details of third-party contractors who received money from the $13 million, including, for each, (i) their name, (ii) the amount received, (iii) the goods or services provided; (e) what are the names of all third-party contractors who received funding through this project implementation and administrative cost stream; (f) what were the amounts paid to each third-party contractor who received funding through this project implementation and administrative cost stream; (g) what were the work descriptions of each third-party contractor who received funding through this project implementation and administrative cost stream; (h) what is the breakdown by school of the 1,954 students who were hired as of December 31, 2023, as E-commerce Advisors; (i) what is the breakdown of the advertising used to advertise these positions; (j) what were the work descriptions of these positions; (k) what is the breakdown by school of the 1,255 youth who were hired to support participating Canadian small and medium enterprises in the implementation of their digital adoption plans; (l) what is the breakdown of the advertising used to advertise these positions; (m) what were the work descriptions of these positions; (n) how many E-commerce Advisors and youths who were hired to support businesses with the implementation of their digital adoption plans were the same person; and (o) what is the breakdown by school of these individuals?

Q-2543² — April 11, 2024 — — With regard to travel expenses related to the Benefits Delivery Modernization Programme, since January 1, 2017: (a) what is the total number of travel expenses filed; (b) what is the total cost of travel expenses filed; (c) what is the cost of travel expenses filed by public servants; (d) what is the cost of travel expenses filed by third-party contractors; (e) what is the cost of flights expensed by public servants; (f) what is the cost of lodgings expensed by public servants; (g) what is the cost of per diems expensed by public servants; (h) what is the cost of flights expensed by third-party contractors; (i) what is the cost of lodgings expensed by third-party contractors; (j) what is the cost of per diems expensed by third-party contractors; and (k) what is the breakdown of (a) to (j) by month and by quarter?

Q-2544² — April 11, 2024 — — With regard to Health Canada’s (HC) approach when they suspect that a vaccine manufacturer has potentially adulterated their own product without appropriate disclosure to HC: (a) how does HC confirm that the potential adulteration exists; (b) does HC procure independent labs to assess the potential adulteration; (c) what measures are available to HC to ensure safety to Canadians and the environment in the event of a deception or adulteration of a therapeutic product under the Food and Drugs Act; (d) regarding the Pfizer/BioNTech mRNA vaccine, were any measures taken under the Food and Drugs Act or under any contract or other regulation with regard to the discovery in July 2023 of the SV40 enhancer/promoter sequences well after the full authorization of this vaccine; (e) if the answer to (d) is affirmative, what measures were taken; (f) if the answer to (d) is negative, why weren’t measures taken; and (g) if the answer to (d) is negative, are measures being planned?

Q-2545² — April 11, 2024 — — With regard to cancer in Canada: (a) what are the top 10 cancers annually since 2010, broken down by province and territory, and, for each cancer, what is the (i) morbidity rate, (ii) mortality rate, (iii) five-year net survival rate; (b) how do the rates in (a)(i), (a)(ii), (a)(iii) compare to the United States; (c) for the rates in (a)(i) and (a)(ii), what is the (i) number of people affected, (ii) cost to the health care system, (iii) total investment compared to the United States; (d) are there any types of cancer on the rise in Canada, and, if so, what are they, broken down by province and territory; (e) what percentage of new patients are offered a diagnostic molecular test in Canada; (f) what percentage of patients are offered a clinical trial in Canada; (g) what percentage of patients are enrolled in a clinical trial in Canada; (h) how many clinical trials have been initiated in Canada annually since 2010; (i) what cancer prevention programs, by cancer type, are funded by the government; (j) how much has the government invested since 2010 in the top 10 cancers, broken down by (i) cancer diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (k) how much has the government annually invested since 2010 in pediatric cancer, broken down by (i) diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (l) how much has the government invested since 2010 in rare cancer, broken down by (i) diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (m) does the Scientific Advisory Committee on Oncology Therapies still exist, and, if so, (i) what is its membership, (ii) when did it last meet, (iii) what was on the agenda of all meetings since 2019; (n) what is the average approval time for phased clinical trials for the top 10 cancers in Canada, broken down by (i) phase I clinical trials, (ii) phase II clinical trials, (iii) phase III clinical trials, (iv) phase IV clinical trials, and how do the approval times in (i), (ii), (iii) and (iv) compare to the United States; (o) what percentage of Canadian children undergoing cancer treatment have access to a clinical trial; (p) what is the average approval time for phased clinical trials for rare cancers in Canada, broken down by (i) phase I clinical trials, (ii) phase II clinical trials, (iii) phase III clinical trials, (iv) phase IV clinical trials, and how do the approval times in (i), (ii), (iii) and (iv) compare to the United States; (q) how many new cancer treatments has Health Canada (HC) approved since 2010 and what percentage have been precision treatments; (r) what are all cancer drugs approved in Canada, and the dates of approval since 2010, broken down by the (i) date the drug was approved in the United States, (ii) provinces and territories where the drug is available, (iii) provinces and territories covering the entire drug cost, (iv) provinces and territories requiring patient payment, (v) additional cost per treatment; (s) how many new cancer treatments has HC approved since 2010 for the top 10 cancers, what percentage have been precision treatments and how do the approval rates and times compare to those in the United States; (t) how many new pediatric cancer treatments has HC approved since 2010 and what percentage have been precision treatments; (u) how many new rare cancer treatments has HC approved since 2010 and what percentage have been precision treatments; (v) on what date was the special access program for drugs first put in place, (i) how many applications have been made for chemotherapy drugs since its creation, (ii) how many times have approvals been made for chemotherapy drugs since its creation, (iii) what is the average approval wait time for a chemotherapy drug, (iv) is there a process for re-application, and, if so, what is the average approval time for re-application of a chemotherapy drug; (w) what are the top 10 pediatric cancers since 2010 annually, broken down by province and territory, and, for each cancer, what is the (i) morbidity rate, (ii) mortality rate, (iii) five-year survival rate by stage, (iv) cost to the healthcare system; (x) for each rate in (w)(i) and (ii), what is the number of people affected; (y) what is the list of all rare cancers in Canada, how many people are affected by rare cancers, and what investments has the government made in their research; (z) what is the process for a clinician to access off-label chemotherapy options for a patient with a rare cancer, including (i) the average approval time, (ii) the re-approval process, and, if any, the average re-approval wait time, (iii) the approval success rate for application, (iv) if relevant, the approval success rate for re-application, (v) the approval success rate when a drug is already approved for use in another country; (aa) what is the average time to diagnosis for each of the (i) top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and what is the average cancer stage at diagnosis and the cost to the healthcare system, since 2010, broken down by province and territory; (bb) what was the average time to diagnosis for each of the (i) top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and what is the average cancer stage at diagnosis and the cost to the healthcare system, broken down by province and territory, and annually from 2019 to 2023; (cc) how many people had to seek diagnosis outside of Canada due to either wait time or lack of diagnostic technology or procedure, and what was the cost to the healthcare system, broken down by province and territory annually since 2010; (dd) how many people had to seek treatment outside of Canada due to either wait time or lack of treatment that was available elsewhere, and what was the cost to the healthcare system, broken down by province and territory annually since 2010; (ee) how many people could not get a recommended chemotherapy because (i) they did not have health insurance, (ii) their health coverage did not cover a chemotherapy drug, (iii) their insurance covered only part of the drug cost, broken down by province and territory; (ff) broken down by province and territory, how many times has the federal special access program been accessed since its inception, (i) how many approvals have been made since its inception, (ii) what is the average approval time, (iii) is there a process for re-application, and, if so, what is the average approval time for re-application; (gg) what has each government invested in cancer treatment since 2010, broken down by province and territory; and (hh) how much has the Canadian Institutes of Health Research invested annually in cancer research since 2010, and specifically what has been invested in (i) the top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and how does this annual total investment compare to the United States?

Q-2546² — April 15, 2024 — — With regard to the communities which comprise the federal electoral district of Carleton, since fiscal year 2005-06: (a) what are the federal infrastructure investments, including direct transfers to municipalities and First Nations, broken down by fiscal year, total expenditure, and project; (b) what are the federal infrastructure investments transferred to regional districts, broken down by fiscal year, total expenditure, and project; (c) what are the federal infrastructure investments transferred to Island Trusts; (d) what are the federal infrastructure investments transferred to First Nations, broken down by First Nation, fiscal year, total expenditure, and project; (e) what is the funding of highways, broken down by fiscal year, total expenditure, and project; and (f) what other infrastructure investments are provided through the funding of national parks, highways, the Building Canada Fund, Infrastructure Canada, the Gas Tax Fund, Small Crafts and Harbours, etc., broken down by fiscal year, total expenditure, and project?

Q-2547² — April 15, 2024 — — With regard to government contracts for veterinary services provided by veterinarians in all federal departments, broken down by fiscal year, since 2017-18: (a) what is the total number of contracts signed; (b) what are the details of all contracts signed, including the (i) agency contracted, (ii) value of the contract, (iii) number of veterinarians provided, (iv) duration of the contract; and (c) what is the total amount of extra costs incurred as a result of relying on contracted services instead of employing veterinarians directly?

Q-2548² — April 15, 2024 — — With regard to government contracts for dentistry services with Indigenous Services Canada, broken down by fiscal year, since 2017-18: (a) what is the total number of contracts signed; (b) what are the details of all contracts signed, including the (i) agency contracted, (ii) value of the contract, (iii) number of dentists provided, (iv) duration of the contract; and (c) what is the total amount of extra costs incurred as a result of relying on contracted services instead of employing dentists directly?

Q-2549² — April 15, 2024 — — With regard to loans and other repayable contributions made by government departments and agencies since November 4, 2015, excluding student loans and those made as part of emergency pandemic relief programs such as the Canada Emergency Business Account: (a) how many instances have occurred where loans or repayable contributions were made and the recipient did not repay the amount owed in accordance with the terms of the agreement, in total and broken down by program under which the funding was provided; (b) what is the dollar value of the loans and contributions in (a); (c) what is the breakdown of (a) and (b) by type of situation or reason (late payments, business insolvency, etc.); (d) of the amount which was not paid back in accordance with the terms of the agreement, how much (i) has been recovered to date, (ii) has not yet been recovered but is expected to be recovered, (iii) has been written-off, by the government; (e) what is the breakdown of (d) by funding program; and (f) what are the details of all instances where the amount written off by the government was in excess of $1 million, including, for each, the (i) recipient, (ii) original amount of funding, (iii) amount written off, (iv) purpose of the funding, (v) date the funding was provided, (vi) date the funding was written off, (vii) reason for the amount being written off?

Q-2550² — April 15, 2024 — — With regard to the cost to the government to administer remittances for the Goods and Services Tax and the Harmonized Sales Tax, broken down by year for each of the last three years: (a) what is the total amount spent to administer the remittances; and (b) what was the total amount spent to administer remittances to businesses generating (i) under $30,000, (ii) between $30,000 and $60,000, (iii) between $60,000 and $100,000, (iv) between $100,000 and $500,000, (v) over $500,000, in revenue?

Q-2551² — April 15, 2024 — — With regard to government investments in businesses that included a commitment to create more than 100 jobs as a result of the investment, since November 4, 2015: for each investment, what was the (i) recipient, (ii) amount of the federal investment, (iii) promised number of jobs created, (iv) number of jobs created to date, (v) date of the investment?

Q-2552² — April 15, 2024 — — With regard to the benefits received by Canadian Armed Forces veterans classified as wartime service veterans and benefits received by veterans who fought under the “special duty service” classification: (a) what are the benefits received by (i) wartime service veterans, (ii) special duty service veterans; (b) how many veterans are receiving “special duty service” benefits for the (i) Persian Gulf War, (ii) Bosnian War, (iii) Afghan War; (c) what is the cost of benefits provided to wartime service veterans in (a) for (i) 2013, (ii) 2014, (iii) 2015, (iv) 2016, (v) 2017, (vi) 2018, (vii) 2019, (viii) 2020, (ix) 2021, (x) 2022, (xi) 2023; (d) what is the cost of benefits provided to “special duty service” veterans in (a) for (i) 2013, (ii) 2014, (iii) 2015, (iv) 2016, (v) 2017, (vi) 2018, (vii) 2019, (viii) 2020, (ix) 2021, (x) 2022, (xi) 2023; (e) what would be the increased cost to provide “wartime service” benefits to Persian Gulf War veterans if benefits were applied for the year (i) 2018, (ii) 2019, (iii) 2020, (iv) 2021, (v) 2022, (vi) 2023; (f) what would be the increased cost to provide “wartime service” benefits to Bosnian war veterans if benefits were applied for the year (i) 2018, (ii) 2019, (iii) 2020, (iv) 2021, (v) 2022, (vi) 2023; and (g) what would be the increased cost to provide “wartime service” benefits to Afghan War veterans if benefits were applied for the year (i) 2018, (ii) 2019, (iii) 2020, (iv) 2021, (v) 2022, (vi) 2023?

Q-2553² — April 15, 2024 — — With regard to inmates in facilities operated by the Correctional Service of Canada, broken down by location, since 2015: (a) how many inmates were on opioid agonist therapy, including sublocade, suboxone or methadone as of January 1 of each year; (b) of the inmates in (a), how many were also concurrently accessing the needle exchange program as of January 1 of each year; (c) how many inmates in total used the needle exchange program each year; and (d) how many inmates accessed other forms of treatment and services, broken down by year and type of treatment and service?

Q-2554² — April 15, 2024 — — With regard to Health Canada (HC), the Public Health Agency of Canada (PHAC) or the National Advisory Committee on Immunization (NACI) and the COVID-19 vaccines: (a) when did the (i) Chief Public Health Officer, (ii) Deputy Chief Public Health Officer, (iii) Chief Medical Officer at Health Canada, (iv) Minister of Health at the time, become aware that the COVID-19 vaccines did not prevent transmission of SARS CoV-2; (b) when were any of the federal health agencies in Canada made aware of this information and by who; (c) when was the information described in (a) delivered to (i) the Office of the Prime Minister, (ii) the Privy Council, (iii) the Cabinet, (iv) the members of the House of Commons; (d) what federal entity, ministry or minister first initiated the concept of “COVID-19 vaccine passports”; (e) on what date did the federal government implement vaccine passports for (i) federal employees, (ii) travel restrictions for all unvaccinated Canadians; (f) in 2021 and 2022, did any personnel from HC, PHAC or NACI engage with or share information about the vaccines’ inability to stop transmission of SARS-CoV-2 with any person involved with (i) the World Health Organization’s Strategic Group of Experts, (ii) Vaccines Together, (iii) the International Vaccine Institute, (iv) Dr. Hanna Nohynek, the World Health Organization’s Chair of Strategic Group of Experts on Immunization; and (g) if the answers to (f)(i) through to (f)(iv) are affirmative, what were the summaries of those discussions or correspondences in relation to the transmission question and the validity of vaccine passports?

Q-2555² — April 15, 2024 — — With regard to government contracts for psychological services and social workers within all federal departments, broken down by fiscal year, since 2017-18: (a) what is the total number of contracts signed for (i) psychological services, (ii) social workers; (b) what are the details of all contracts signed, including the (i) agency contracted, (ii) value of the contract, (iii) number of psychologists or social workers provided, (iv) duration of the contract; and (c) what is the total amount of extra costs incurred as a result of relying on contracted services instead of employing psychologists and social workers directly?

Q-2556² — April 15, 2024 — — With regard to government contracts for medical services and nursing services within all federal departments, broken down by fiscal year, since 2017-18: (a) what is the total number of contracts signed for (i) medical services provided by a doctor of medicine, (ii) nursing services provided by registered nurses or nurse practitioners; (b) what are the details of all contracts signed, including the (i) agency contracted, (ii) value of the contract, (iii) number of medical doctors, registered nurses, or nurse practitioners provided, (iv) duration of the contract; and (c) what is the total amount of extra costs incurred as a result of relying on contracted services instead of employing medical doctors, registered nurses or nurse practitioners directly?

Q-2557² — April 15, 2024 — — With regard to the Canadian Forces Housing Agency, since January 1, 2021: (a) how many Canadian Armed Forces personnel are on a waitlist for military housing, broken down by month and year; and (b) what is the average time military members are on the agency’s waitlist?

Q-2558² — April 16, 2024 — — With regard to the final contract awarded by the government to the CIMA engineering firm by Windsor-Detroit Bridge Authority (WDBA) for the construction of the Gordie Howe International Bridge: (a) what is the total value of the contract; (b) what were the determining factors of CIMA's submission being chosen over that of the Stanley Consultants engineering firm; (c) what are the details of all documents, including briefing notes, meeting minutes, draft documents, presentations, letters, contracts, agreements, communications, emails and recorded meetings regarding the hiring of Stanley Consultants, the dismissal of Stanley Consultants, and the hiring of CIMA; and (d) what are the details of all records, including documents and communications from April 2017 to April 2024, involving the (i) WDBA Board Chairs, (ii) employees of CIMA, (iii) employees of Stanley Consultants, (iv) WDBA Chief Executive Officer, (v) WDBA Chief Legal Officer, (vi) WDBA Chief Operations Officer, (vii) WDBA Chief Relations Officer, (viii) WDBA Chief Capital Officer, (ix) WDBA Chief Financial and Administrative Officer, (x) WDBA Associate Vice President and Chief Bridge Engineer?

Q-2559² — April 16, 2024 — — With regard to budget 2023 and the government’s action to crack down on junk fees: (a) what are the details of all consultations and meetings with regulatory agencies, provinces and territories on this subject, including the (i) date of the consultation, (ii) agency or officials consulted, (iii) outcomes of the consultation; (b) what indicators and targets does the government use to measure progress on cutting junk fees; and (c) what efforts have been done by the government to (i) set new NSF fee caps, (ii) enhance low-cost accounts, (iii) expand eligibility for no-cost accounts?

Q-2560² — April 16, 2024 — — With regard to the Department of National Defence (DND) and existing contracts with IMP Aerospace & Defence (IMP) since fiscal year 2018-19: (a) what are the details of all contracts between the DND and IMP concerning servicing and maintaining search and rescue aircraft, including the (i) contract number, (ii) date of the contract, (iii) contract value, (iv) location of work being done, (v) date by which the contracted work will be completed, (vi) conditions on labour including sick leave requirements; (b) of the contracts in (a), which contracts include (i) minimum pay standards, (ii) minimum staffing requirements, (iii) policies regarding staff mobility, including moving expenses, (iv) limits on overtime hours worked; (c) what reporting requirements exist for IMP to ensure compliance with the contracts in (a); (d) what mechanisms does the DND have to ensure compliance with the contracts in (a); and (e) has the DND used any of the mechanisms in (d) to enforce compliance?

Q-2561² — April 16, 2024 — — With regard to government contracts for services provided by a nutritionist or dietician and services provided by a pharmacist within all federal departments, broken down by fiscal year, since 2017-18: (a) what is the total number of contracts signed for (i) services provided by a nutritionist or dietician, (ii) services provided by a pharmacist; (b) what are the details of all contracts signed, including the (i) agency contracted, (ii) value of the contract, (iii) number of nutritionists, dieticians or pharmacists provided, (iv) duration of the contract; and (c) what is the total amount of extra costs incurred as a result of relying on contracted services instead of employing nutritionists, dieticians or pharmacists directly?

Q-2562² — April 16, 2024 — — With regard to government contracts for occupational therapy and physiotherapy services provided by occupational therapists and physiotherapists within all federal departments, broken down by fiscal year, since 2017-18: (a) what is the total number of contracts signed; (b) what are the details of all contracts signed, including the (i) agency contracted, (ii) value of the contract, (iii) number of occupational therapists and physiotherapists provided, (iv) duration of the contract; and (c) what is the total amount of extra costs incurred as a result of relying on contracted services instead of employing occupational therapists and physiotherapists directly?

Q-2563² — April 16, 2024 — — With regard to Indigenous Services Canada (ISC), since 2015: (a) how many forensic audits (i) have been conducted, (ii) are currently ongoing; (b) which First Nations communities (i) have been audited, (ii) are in the process of a forensic audit; (c) what were the reasons for initiating each of the audits in (b); and (d) for each audit that has been completed, (i) which community was audited, (ii) what were the results, (iii) how can the public access the findings, including the website where they are available, (iv) what action, if any, did ISC take in response to the audit?

Q-2564² — April 16, 2024 — — With regard to the new reporting requirements for bare trusts introduced in January 2023: how many T3 Income Tax and Information Returns (T3 returns) including schedule 15 (Beneficial Ownership Information of a Trust) were filed for the 2023 tax year?

Q-2565² — April 16, 2024 — — With regard to the eligibility review process of the Canada Child Benefit for shared custody arrangements: (a) what measures are being taken by the Government of Canada to verify the appropriate payment amount based on the percentage of time the child spends with each individual; (b) what guidelines are in place to prevent inequality between recipients; and (c) if completed, what were the findings of the Gender-based Analysis Plus?

Q-2566² — April 16, 2024 — — With regard to the Canada Child Benefit: (a) how many recipients currently receive the Canada child benefit; (b) of the recipients in (a), what is the breakdown between (i) spouses or common-law partners who reside in the same home as the child, (ii) individuals in child custody arrangements; (c) of the recipients in (b)(ii), what is the breakdown of (i) individuals who about equally split the time spent with the child with another individual (between 40% and 60%), (ii) individuals who spent most of the time with the child (more than 60%), (iii) individuals who spent less of the time with the child (less than 60%), (iv) individuals who only spent a temporary period (e.g. summer period) with the child?

Q-2567² — April 16, 2024 — — With regard to government information on energy use on Canadian farms from 2005 to 2023, broken down by year: how much energy in petajoules was sourced from (i) electricity, (ii) natural gas, (iii) motor gasoline, (iv) diesel fuel oil, (v) light fuel oil, (vi) kerosene, (vii) heavy fuel oil, (viii) propane, (ix) steam, (x) coal?

Q-2568² — April 16, 2024 — — With regard to the appearance of the Deputy Minister of Public Service and Procurement Canada, Arianne Reza, at the Standing Committee on Government Operations and Estimates on February 28, 2024: (a) what are the names of the 635 IT firms mentioned by the deputy minister; (b) which departments, agencies, and Crown corporations used the services of the 635 IT firms; (c) what is the total cost per contract awarded to the 635 IT firms; and (d) broken down by each department, agency, and Crown corporation that awarded contracts to the firms, what was the total (i) amount of expenditures, (ii) total number of contracts, with each firm, broken down by year since 2015?

Q-2569² — April 16, 2024 — — With regard to the Canada Revenue Agency: in the "Residence Information" section of the T1 Income Tax and Benefit Return, how many taxpayers indicated that they had ceased to be a resident of Canada for income tax purposes by entering a departure date that was between January 1, 2015, and April 16, 2024, broken down by year and income bracket?

Q-2570² — April 16, 2024 — — With regard to the final report of the Minister of National Defence’s Advisory Panel on Systemic Racism and Discrimination: (a) how and to what extent have the findings in Part III, section 6, entitled “Re-Defining Chaplaincy”, been rejected, adopted, actioned, interpreted, or otherwise implemented; (b) how and to what extent has Part III, recommendation 6.1 been adopted, actioned, or otherwise implemented; (c) how and to what extent has Part III, recommendation 6.2 been adopted, actioned, or otherwise implemented; (d) how and to what extent has Part III, recommendation 6.3 been adopted, actioned, or otherwise implemented; (e) how and to what extent has Part III, recommendation 6.4 been adopted, actioned, or otherwise implemented; (f) what published policies, practices, instructions, or orders have been promulgated, amended, updated, or changed as a result of the findings, observations, and recommendations in Part III, section 6 of the report; (g) how and to what extent have decisions respecting hiring, promotion, evaluation, contracting, or termination in the Canadian Armed Forces been influenced by the findings, observations, and recommendations in Part III, section 6 of the report; (h) how and to what extent have decisions respecting hiring, promotion, evaluation, contracting, or termination in the Department of National Defence (DND) been influenced by the findings, observations, and recommendations in Part III, section 6 of the report; (i) how and to what extent has Canadian Armed Forces (CAF) operational decision-making been influenced by the findings, observations, and recommendations in Part III, section 6 of the report; (j) how and to what extent has DND operational decision-making been influenced by the findings, observations, and recommendations in Part III, section 6 of the report; and (k) how has the composition of CAF chaplains changed since the publication of the report, broken down by number of chaplains and faith or spiritual affiliation of chaplains, as of the first day of January, April, July, and October of 2022 and 2023, and as of the first day of January and April 2024?

Q-2571² — April 17, 2024 — — With regard to government security clearances as of April 1, 2024: (a) how many personnel have an active or currently valid security clearance from the Government of Canada, broken down by (i) institution, (ii) status of employment (e.g. employee, contractor, potential contractor, former employee, etc.), (iii) level of security clearance; (b) how long do Cabinet ministers and other individuals appointed to the King’s Privy Council have the security clearances described in the witness statement of the Minister of Public Safety, Democratic Institutions and Intergovernmental Affairs before the Public Inquiry into Foreign Interference in Federal Electoral Processes and Democratic Institutions; (c) what process exists to routinely review the authority of Cabinet ministers and other individuals appointed to the King’s Privy Council to access classified information on a need to know basis; and (d) does the process in (c) require the same frequency of reviewing and updating that is in place for all other cleared personnel (i.e. five years for Top Secret, 10 years for Secret)?

Q-2572² — April 17, 2024 — — With regard to Parks Canada’s most recent update to their logo: (a) what were the expenses incurred, in total and broken down by type of expense; (b) what are the details of all contracts with external suppliers, consultants, and professional services related to the updated logo, including, for each, the (i) vendor, (ii) description of the goods and services provided, (iii) value or amount of the contract; (c) when did Parks Canada initially begin the process to update their logo; (d) on what date did Parks Canada submit their new logo to the Canadian Intellectual Property Office; and (e) what are all costs incurred by Parks Canada to replace previous logos, including a breakdown of the costs incurred at each location where the logo has been replaced?

Q-2573² — April 17, 2024 — — With regard to agreements signed by Parks Canada to allow hunting or trapping within national parks or on Parks Canada land, since 2016: what are the details of each agreement, including, for each, the (i) date it was signed, (ii) names of the parties with whom the agreement was signed, (iii) summary of the terms of the agreement, (iv) start and end dates, (v) website where the agreement is made available to the public, (vi) animals and species permitted to be hunted or trapped?

Q-2574² — April 17, 2024 — — With regard to the Department of Housing, Infrastructure and Communities and the costs associated with its creation, as legislated in division II of the 2023 Fall Economic Statement: (a) what are the total costs incurred to date associated with the creation of the Department of Housing, Infrastructure and Communities; (b) what is the breakdown of (a) by type of expense (office space renovation, new signage, branding costs, etc.); (c) what are the total annual costs associated with the ongoing operations of the Department of Housing, Infrastructure and Communities; (d) how many employees work for the Department of Housing, Infrastructure and Communities; (e) how many of the employees (i) are new government employees, (ii) were employed by Infrastructure Canada immediately prior to working for the newly formed department, (iii) were employed by a department other than Infrastructure Canada immediately prior to working for the newly formed department, broken down by previous department of employment; (f) as a result of the creation of the Department of Housing, Infrastructure and Communities, how many houses will be built (i) in 2026, (ii) by 2030; and (g) how will the government track and measure the progress and success of the Department of Housing, Infrastructure and Communities?

Q-2575² — April 17, 2024 — — With regard to expenditures on consultants by Parks Canada since November 4, 2015: (a) what is the total amount of expenditures incurred on consultants; (b) what are the details of all such contracts under object codes (i) 0431 (Scientific consultants), (ii) 0446 (Training consultants), (iii) 0473 (Information technology and telecommunications consultants), (iv) 0491 (Management consulting), (v) 0422 (Engineering consultants – Construction), (vi) 0423 (Engineering consultants – Other), (vii) 0301 (Advertising services), (viii) 0351 (Communications professional services not elsewhere specified), (ix) 0352 (Public relations services); and (c) what are the details of the contracts in (b), including the (i) amount, (ii) vendor, (iii) date of the contract, (iv) duration of the contract, (v) description of the services provided, (vi) reason or purpose of the contract?

Q-2576² — April 17, 2024 — — With regard to operational investments by Parks Canada, broken down by national park, national marine conservation area, and national historic site: (a) what are the details of all capital projects or improvements currently ongoing, including, for each, the (i) costs incurred to date, (ii) project budget, (iii) project description, (iv) start date, (v) original estimated completion date, (vi) current estimated completion date, (vii) reason for the project delay, if applicable, (viii) location; (b) of the capital projects or improvements in (a), which are projected to exceed the original budget; and (c) for those projects in (b), what is the reason the original budget was exceeded?

Q-2577² — April 17, 2024 — — With regard to surveys commissioned by the Government of Canada since January 1, 2021, broken down by department or agency and by year: for each survey, (i) what was the purpose, (ii) what were all questions asked, (iii) what were the answers received, (iv) what costs were associated with the survey, in total and broken down by type of expense, (v) what external suppliers and consultants were used to commission the survey, (vi) what external suppliers and consultants were used to analyze and collect the results of the survey, (vii) how many responses were received for each survey, (viii) who did the survey target, (ix) was the survey available to all Canadians, and if not, who was able to respond to the survey?

Q-2578² — April 17, 2024 — — With regard to the government’s creation of the Sustainable Jobs Partnership Council, the Regional Energy and Resource Tables, and the Sustainable Jobs Secretariat, through Bill C-50, An Act respecting accountability, transparency and engagement to support the creation of sustainable jobs for workers and economic growth in a net-zero economy: (a) has the government made a list of potential candidates for the positions within each of these entities; (b) how many positions will there be within each of these entities, broken down by title of position; (c) are there qualifications required for an appointment to one of these entities, and, if so, what are they, broken down by position; (d) are there criteria which disqualify someone from receiving an appointment or serving their term, and, if so, what are they, broken down by position; and (e) what is the amount of compensation being provided for serving in each position?

Q-2579² — April 17, 2024 — — With regard to the carbon tax and reports that individuals and families living in provinces and locations without the federal carbon tax are receiving the Canada Carbon Rebate (CCR): (a) how many individuals and families with home addresses in Quebec received a CCR payment in (i) 2023, (ii) 2024, and what was the total amount paid out to those recipients; and (b) how many individuals and families with mailing addresses outside of Canada received a CCR payment in (i) 2023, (ii) 2024, and what was the total amount paid to those recipients?

Q-2580² — April 17, 2024 — — With regard to Canadian Armed Forces (CAF) members based out of Canadian Forces Base Valcartier (CFB Valcartier), each year between 2016 and 2024: how many CAF members out of CFB Valcartier have been discharged, in total, and broken down by release category (voluntary, compulsory, medical, etc.) and by reason (service completed, misconduct, etc.)?

Q-2581² — April 17, 2024 — — With regard to Natural Resources Canada's (NRCan) 2016 Ministerial Review of the Trans Mountain Pipeline Expansion Project: why does NRCan no longer have a record of (i) the presentations made to the review panel at the public engagement meetings, (ii) the notes taken at the public engagement meetings?

Q-2582² — April 17, 2024 — — With regard to the Canada Emergency Business Account (CEBA), which is administered by Export Development Canada: (a) what is the total number of loans and total capital (i) issued from the CEBA program since it was first launched on April 9, 2020, (ii) paid back in full by April 17, 2024, (iii) paid back in full by December 31, 2023, (iv) issued and refinanced before March 28, 2024, (v) repaid in full by March 28, 2024; (b) what is the breakdown of (a) by province and territory; (c) for each province and territory in (b), what is the breakdown by each sector of the tourism industry, including (i) accommodation, (ii) transportation, (iii) food and beverage services, (iv) recreation and entertainment, (v) travel services; and (d) how many loans have been referred to collections as of April 17, 2024?

Q-2583² — April 18, 2024 — — With regard to Health Canada (HC), the Public Health Agency of Canada (PHAC), the National Advisory Committee on Immunization (NACI) and any communications in 2020 or 2021 regarding mask exemptions, COVID-19 vaccines, medications to treat COVID-19, or any other public health messaging about COVID-19: (a) did (i) the Minister of Health, (ii) the Deputy Minister of Health, Dr. Steven Lucas, (iii) the Chief Public Health Officer, (iv) the Deputy Chief Public Health Officer, (v) the Chief Medical Officer at Health Canada, (vi) any personnel from HC, (vii) any personnel from the PHAC, (viii) any personnel from the NACI, (ix) any firm contracted by or through HC, PHAC, or NACI, communicate or correspond, directly or indirectly, with the College of Physicians and Surgeons of Ontario (CPSO); (b) if any of the answers to (a)(i) through (a)(ix) are affirmative, (i) when did these communications occur, (ii) what are the summaries of those communications; (c) did any of the individuals or agencies in (a)(i) through (a)(ix) of (a) communicate with the Health Professions Regulatory Advisory Council (HPRAC); and (d) if the answer to (c) is affirmative, what are the summaries of those communications?

Q-2584² — April 18, 2024 — — With regard to the Minister of Rural Economic Development’s announcement on improving connectivity in rural Saskatchewan made on March 17, 2023, since the announcement: (a) how much of the $37 million in announced funding has been spent to date; (b) what projects, if any, have received funding; and (c) have any of the Hanson Lake Road projects been approved for this funding, including (i) Hanson Lake Road A UBF-3500, (ii) Hanson Lake Road B UBF-3501, (iii) Hanson Lake Road C UBF-3502, (iv) Creighton UBF-3503, (v) Hanson Lake Road UBF-3506, (vi) other projects?

Q-2585² — April 25, 2024 — — With regard to the Canada Revenue Agency, broken down by tax year since 2019: (a) how many trusts and corporations assessed and paid capital gains and what was the total amount of capital gains collected from this group; (b) how many trusts and corporations assessed and paid taxes on capital gains (i) of less than $50,000, (ii) between $50,000 and $100,000, (iii) between $100,000 and $250,000, (iv) of more than $250,000; and (c) for each group in (b), what was the total amount collected in taxes on capital gains?

Q-2586² — April 25, 2024 — — With regard to the First Nations and Inuit Policing Program, and the Auditor General of Canada's report entitled "Report 3 - First Nations and Inuit Policing Program": (a) what is the breakdown of the $930 million in funding, referred to in paragraph 3.21 of the report, by province and territory; (b) how is the funding broken down by (i) self-administered police service agreements, (ii) Community Tripartite Agreements; (c) why, according to paragraph 3.23 of the report, didn’t Public Safety Canada disburse about $17 million of the $196 million program funds available in the 2022-23 fiscal year; and (d) why, according to paragraph 3.24 of the report, didn’t Public Safety Canada verify whether the funds transferred to the RCMP were being used for program costs, as opposed to other police services?

Q-2587² — April 25, 2024 — — With regard to the National Trade Corridors Fund administered by Transport Canada, as of April 2024: (a) of the projects funded, how many (i) have not started, (ii) are underway, (iii) have been completed; and (b) for each project, what is the (i) timeline, (ii) objective, (iii) location?

Q-2588² — April 25, 2024 — — With regard to government contracts with McKinsey & Company and the report from the Office of Procurement Ombud, entitled "Procurement Practice Review of Contracts Awarded to McKinsey & Company": (a) what are the details of the 25 non-competitive contracts listed on page four of the report, including, for each, (i) the date of the contract, (ii) the title, (iii) the file number, (iv) the value of each contract, (v) the department, (vi) the reason for sole sourcing, (vii) who authorized the sole sourcing, (viii) the purpose of the contract and services provided; (b) what are the details of the seven competitive contracts listed on page four of the report, including, for each, the (i) date of the contract, (ii) title, (iii) file number, (iv) value of the contract, (v) department, (vi) purpose of the contract and services provided; and (c) why did the government change their procurement strategy to allow two contracts to be awarded to McKinsey & Company when they were originally ineligible, in the instance outlined on page six, paragraph 26 of the report?

Q-2589² — April 25, 2024 — — With regard to government payments: how many recipients of (i) the Canada Pension Plan, (ii) Old Age Security, (iii) the Guaranteed Income Supplement, (iv) Canada Pension Plan disability benefits, (v) Employment Insurance benefits, (vi) the Child Tax benefit, (vii) the Survivor’s Pension, received their payments, broken down by method of receival (e.g. direct deposit, physical cheque mailed by the government, etc.), by province or territory (or abroad, if applicable) and by year, since 2015?

Q-2590² — April 25, 2024 — — With regard to the Canada Pension Plan Investment Board (CPPIB): (a) what are the details of all advertisement campaigns by the CPPIB since November 4, 2015, including, for each, the (i) title, (ii) name of the advertising campaign, (iii) objective, (iv) total costs associated with the advertisement campaign, (v) breakdown of the costs; and (b) for each advertisement campaign in (a), was it (i) website based, (ii) paper based, (iii) radio based, (iv) television based?

Q-2591² — April 25, 2024 — — With regard to the number and value of contracts awarded to GC Strategies and Coredal Systems Consulting, from January 1, 2011, to February 16, 2024, that were provided by the Treasury Board Secretariat to the Standing Committee on Government Operations and Estimates on April 16, 2024: what are the details for each deliverable associated with the contracts, including, for each, the (i) date that the deliverable was finished, (ii) title, (iii) summary of the recommendations, (iv) file number, (v) website where the deliverable is available online, if applicable?

Q-2592² — April 25, 2024 — — With regard to the government's participation in the sixth session of the United Nations Environment Assembly (UNEA-6) in Nairobi, Kenya: (a) what are the total expenditures incurred by the government to date related to the assembly, broken down by type of expense; (b) what was the total number of attendees that the government paid for, including the (i) official title and department or organization of each individual, (ii) total expenditures incurred for each entity in (i), broken down by type of expense; (c) for the delegation’s accommodations in Kenya, (i) what hotels were used, (ii) how much was spent at each hotel, (iii) how many rooms were rented at each hotel and for how many nights, (iv) what were the room rates paid at each hotel and the number of rooms rented at each rate, (v) who stayed in each of the rooms in (iv), broken down by room rate; (d) what were the details of the Minister of Environment and Climate Change’s accommodation expenditures, including the (i) daily rate, (ii) accommodating venue; (e) what are the details of the total hospitality expenditures, broken down by (i) date, (ii) amount, (iii) location, (iv) name of any commercial establishment or vendor involved in the hospitality activity, (v) number of attendees, (vi) the description of the event, (vii) the description of goods and services purchased; (f) what are the details of all ground transportation expenditures, including, for each, the (i) date, (ii) amount, (iii) vendor, (iv) point of origin, (v) destination, (vi) make and model of each vehicle used, (vii) type of vehicle (e.g. gas, electric, hybrid), (viii) whether a chauffeur or driver was included, (ix) names and titles of the passengers or individuals who incurred the expense; and (g) what are the details of all expenditures on gifts related to the assembly, including, for each, the (i) value, (ii) description, (iii) vendor from whom it was purchased, (iv) recipient?

Q-2593² — April 25, 2024 — — With regard to the Community Futures Program, since 2019: outside of core funding, what are the details of all additional funding which has been given to organizations which implement the program such as the Community Futures Development Corporations, including, for each instance, the (i) recipient, (ii) amount, (iii) date, (iv) purpose of the funding, (v) program under which the funding was provided?

Q-2594² — April 25, 2024 — — With regard to loans provided directly by regional development agencies under the Regional Relief and Recovery Fund: what are the details, including, for each, the (i) date, (ii) recipient, (iii) advanced loan value, (iv) location of the borrower, (v) amount still owing?

Q-2595² — April 25, 2024 — — With regard to the communities which comprise the federal electoral district of Courtenay—Alberni, since the 2005-06 fiscal year: (a) what are the federal housing investments, including direct transfers to the municipalities and First Nations, for the communities of (i) Tofino, (ii) Ucluelet, (iii) Port Alberni, (iv) Parksville, (v) Qualicum Beach, (vi) Cumberland, (vii) Courtenay, (viii) Deep Bay, (ix) Dashwood, (x) Royston, (xi) French Creek, (xii) Errington, (xiii) Coombs, (xiv) Nanoose Bay, (xv) Cherry Creek, (xvi) China Creek, (xvii) Bamfield, (xviii) Beaver Creek, (xix) Beaufort Range, (xx) Millstream, (xxi) Mt. Washington Ski Resort, broken down by fiscal year, total expenditure, and project; (b) what are the federal housing investments transferred to the (i) Comox Valley, (ii) Nanaimo, (iii) Alberni-Clayoquot, (iv) Powell River, Regional Districts, broken down by fiscal year, total expenditure, and project; and (c) what are the federal housing investments transferred to the Island Trusts of (i) Hornby Island, (ii) Denman Island, (iii) Lasquetti Island, broken down by fiscal year, and total expenditure?

Q-2596² — April 25, 2024 — — With regard to Site 06875001 – Camp Bouchard, Ex Ammo Dump, on the Federal Contaminated Sites Inventory: (a) what measures are currently underway to decontaminate the site; (b) what is the plan and timeline to decontaminate the site; and (c) what amounts have been allocated to decontaminate the site?

Q-2597² — April 25, 2024 — — With regard to the Canada Border Services Agency’s (CBSA) decision to have Employment Professionals Canada (EPC) as their permitted offload and reload service provider: (a) what are the details of the arrangement between the CBSA and EPC that requires truckers to use EPC’s services during examination, including (i) when the agreement was signed, (ii) what the terms of the agreement (financial and otherwise) are, (iii) who at the CBSA authorized the agreement; (b) is the CBSA aware of the reports alleging that EPC is engaging in price gouging and charging some truckers thousands of dollars for re-loading services that were previously available to truckers, and, if so, what was the CBSA’s reaction to these reports; (c) is the government concerned that the increased costs to truckers resulting from the use of EPC’s services will be passed on to consumers, and, if so, what action will be taken in response; (d) does EPC provide the offloading and reloading services itself in all cases, or does it subcontract these services to other parties; (e) if EPC’s services are subcontracted to other firms, why did the CBSA decide to pay a middleman rather than directly paying the vendor who provides the loading and offloading services; (f) does the CBSA pay EPC to be the provider or does EPC pay the CBSA for the right to be the exclusive supplier, and how much is being paid; (g) what measures, if any, has the CBSA put in place to ensure that truckers are not being charged more than the fair market rate for loading and offloading services; (h) prior to this arrangement with EPC, who provided these services and at what rate; (i) was there a conflict of interest analysis completed given EPC’s involvement with other businesses within the supply chain space, and, if so, what were the results of that analysis; (j) do EPC’s employees have the proper security clearance to provide these services, and who at the CBSA is responsible for regularly ensuring those clearances are valid; and (k) was this a sole source contract?

Q-2598² — April 25, 2024 — — With regard to duty of care of athletes and athlete accidents, injuries, concussions, eating disorders and mental health challenges: (a) does Canada have a duty of care to carded athletes, and, if so, what is the policy; (b) do (i) coaches, (ii) medical personnel, (iii) other individuals on an athlete’s team, have a duty of care to carded athletes, and, if so, what is the policy; (c) do any of the provinces and territories recognize a duty of care to (i) young people participating in organized sport in school, (ii) athletes and young people participating in organized sport outside of school, and, if so, which provinces and territories, and what are their respective policies; (d) does Canada have a duty to report any abuse of athletes, and, if so, what are the details, including, (i) is it immediate, (ii) is it direct, (iii) is it ongoing, (iv) does it address confidentiality, (v) does it require documenting action, (vi) what is the policy; (e) do any of the provinces and territories have a duty to report any abuse of children participating in organized sport in school, and, if so, what are the details, including (i) is it immediate, (ii) is it direct, (iii) is it ongoing, (iv) does it address confidentiality, (v) does it require documenting action, (vi) what are any policies; (f) do any of the provinces and territories have a duty to report any abuse of athletes and young people participating in organized sport outside of school, and, if so, what are the details, including (i) is it immediate, (ii) is it direct, (iii) is it ongoing, (iv) does it address confidentiality, (v) does it require documenting action, (vi) what are any policies; (g) does a registry of athlete accidents and injuries in Canada, for carded athletes, exist, and, if so, what are the details, including, (i) the physical and mental health injuries being tracked, (ii) the period for which injuries are tracked, (iii) the number of injuries, broken down by sport, (iv) the time lost from training, (v) the time lost from education, (vi) the time lost from work, (vii) the treatments required, (viii) whether the full cost of necessary treatment is covered, and by whom, (ix) any cost to the athlete for treatment, (x) long-term health impacts, if any; (h) do registries of athlete accidents and injuries in Canada exist at the provincial or territorial level, and, if so, what are the details, including, the (i) physical and mental health injuries being tracked, (ii) period for which injuries are tracked, (iii) number of injuries, broken down by sport, (iv) time lost from training, (v) time lost from education, (vi) time lost from work, (vii) treatments required, (viii) long-term health impacts, if any; (i) have any sport deaths occurred in Canada, and, if so, what are the details, including, (i) the number of deaths, (ii) the year, (iii) the sport, (iv) the cause of death, (v) was there an investigation, (vi) were there recommendations to prevent similar accidents in the future; (j) have any sport paralysis cases occurred in Canada, and, if so, what are the details, including, (i) the number of cases, (ii) the year, (iii) the sport, (iv) the cause of paralysis, (v) was there an investigation, (vi) were there recommendations to prevent similar accidents in the future; (k) have any severe brain injury cases occurred in Canada because of sport, and, if so, what are the details, including, (i) the number of cases, (ii) the year, (iii) the sport, (iv) the cause of the brain injury, (v) was there an investigation, (vi) were there recommendations to prevent a similar accident in the future, (vii) were there long-term health impacts, and, if so, what were they; (l) does a registry of concussions for carded athletes exist, and, if so, what are the details, including, (i) the concussion rate among carded athletes, broken down by sport, (ii) whether the concussion rate is increasing or decreasing, broken down by sport, (iii) in which sports are concussions most prevalent; (m) how is “safe” defined with respect to head injuries; (n) are head injury protocols designed to be safe, broken down by sport; (o) how is “reasonable action” defined with respect to head injuries; (p) what National Sport Organizations (NSOs) take reasonable action to protect athletes from permanent injury caused by repetitive concussive and sub-concussive blows; (q) which, if any, NSOs have a policy regarding subclinical hits; (r) which, if any, NSOs have a policy regarding (i) head injury education, (ii) prevention of head injury, (iii) injury assessment, (iv) injury management; (s) do preventive head injury protocols exist, and, if so, what are the details, including (i) the sport, (ii) the protocol, (iii) how it reflects the best available science; (t) what, if any, certification, and training is required of (i) coaches, (ii) trainers, (iii) members of an athlete’s team, regarding mental health; (u) what, if any, work is being done to look at the mental health of carded athletes, including, but not limited to, (i) the creation of safe spaces, (ii) the consideration of stress, anxiety and depression, (iii) the consideration of cumulative impacts of injury, overtraining and uncertain futures, (iv), support before, during and after major competitions, (v) recognition of athletes’ efforts; (v) what, if any, certification and training is required of (i) coaches, (ii) trainers, (iii) members of an athlete’s team, on physical development, including basic needs, cognitive development, social development, risk, and resilience; and (w) is any tracking done regarding disordered eating rates among carded athletes, and, if so, what are the details, including (i) the rates, broken down by sport, (ii) whether eating disorders are increasing or decreasing, (iii) what, if any, work is being done regarding power dynamics and culture of dietary practices, (iv) who has the medical training to provide nutritional advice, (v) what, if any, work is being done regarding body shaming, (vi) what, if any, work is being done regarding reducing stigma?

Q-2599² — April 29, 2024 — — With regard to the Age Well at Home initiative: (a) how many organizations submitted projects between June 8, 2022, and July 29, 2022, in the constituency of Thérèse-De Blainville and, of these project submissions, how many (i) were approved, (ii) were denied, (iii) have not yet received a response; and (b) of the project applications in the constituency of Thérèse-De Blainville that have not yet received a response, (i) what are the estimated timelines for processing these applications, (ii) what are the reasons for these processing delays, (iii) will the amounts approved initially for these applications be adjusted for inflation?

Q-2600² — April 29, 2024 — — With regard to asylum claims made by individuals who arrived in Canada on a student visa, since 2018: how many claims (i) were accepted, (ii) were rejected, (iii) are still being processed, in total and broken down by the school in which the claimant was enrolled when the asylum claim was made?

Q-2601² — April 29, 2024 — — With regard to stakeholders that were consulted by the Deputy Prime Minister and Minister of Finance about what to include in budget 2024: (a) what were the names and titles of all stakeholders consulted; and (b) what are the details, including the date, location, and manner in which each of the stakeholders in (a) were consulted?

Q-2602² — April 29, 2024 — — With regard to the Canada Revenue Agency's (CRA) response to the Privacy Commissioner of Canada's special report to Parliament on February 15, 2024, indicating that a major privacy breach at the CRA involved "vast amounts of sensitive personal information" and that the CRA needed stronger security safeguards: (a) does the CRA accept the conclusions of the Privacy Commissioner that the current process and procedures that govern the handling of sensitive personal information are inadequate; (b) what steps is the CRA undertaking to rectify this lack of safeguards and due diligence to give Canadians confidence that their personal, sensitive and private information is secure with the CRA; (c) what steps is the CRA taking to limit collection until it can be confident that information can be properly secured; and (d) does the CRA take the position that seeking sensitive information from businesses with no sales or confirmed tax obligations would be a misuse of the Universal Periodic Review provisions, and, if not, why not?

Q-2603² — April 29, 2024 — — With regard to usage of the government's fleet of Challenger aircraft, since October 27, 2023: what are the details of the legs of each flight, including the (i) date, (ii) point of departure, (iii) destination, (iv) number of passengers, (v) names and titles of the passengers, excluding security or Canadian Armed Forces members, (vi) total catering bill related to the flight, (vii) volume of fuel used, or an estimate, (viii) amount spent on fuel?

Q-2604² — April 29, 2024 — — With regard to usage of the government's fleet of Airbus and Polaris aircraft since September 1, 2023: what are the details of the legs of each flight, including the (i) date, (ii) point of departure, (iii) destination, (iv) number of passengers, (v) names and titles of the passengers, excluding security or Canadian Armed Forces members, (vi) total catering bill related to the flight, (vii) volume of fuel used, or an estimate, (viii) amount spent on fuel, (ix) type of aircraft?

Q-2605² — April 29, 2024 — — With regard to the 140 conflict of interest declarations filed in the 2022-23 fiscal year, and the 162 conflict of interest declarations filed in the 2023-24 fiscal year concerning public servants employed in the core public administration who were involved in contractual relationships with the Government of Canada, broken down by fiscal year: (a) what is the breakdown of the declarations by department, agency or other government entity by which the public servant was employed; (b) what are the names of the vendors which have contracts with the government that were the subjects of the declarations; and (c) what are the details of each contract provided to the vendors in (b), including, for each, the (i) department, agency, or other government entity that signed the contract, (ii) vendor, (iii) date, (iv) amount, (v) description of goods or services, (vi) manner in which the contract was awarded (sole-sourced, competitive bid)?

Q-2606² — April 29, 2024 — — With regard to human resource complaints submitted by employees of Innovation, Science and Economic Development Canada, since January 1, 2016, broken down by year: (a) what was the total number of complaints broken down by the (i) name of the agency or Crown corporation employing the complainant, (ii) reason for the complaint, (iii) type of resolution or follow-up action that occurred; and (b) what was the average time between a complaint being filed and the matter being settled or otherwise concluded?

Q-2607² — April 29, 2024 — — With regard to tax owed to the government for unpaid excise tax on cannabis: (a) what is the current amount owed, in total and broken down by the province or territory of the entity owing tax; (b) how many separate taxpaying entities have unpaid excise tax on cannabis; and (c) what is the breakdown of (a) and (b) by the tax year from which the unpaid tax is owed?

Q-2608² — April 29, 2024 — — With regard to lethal and non-lethal military export control permits currently awaiting a governor-in-council decision: what are details of each item, including the (i) vendor, (ii) item description, (iii) dollar value of the export, (iv) date on which the control permit was referred to the governor-in-council for a decision, (v) country for which the item is destined?

Q-2609² — April 29, 2024 — — With regard to digital marketing firms contracted by the government to conduct digital marketing since 2016: what are the details of all contracts, including the (i) name of the firm contracted, (ii) commission provided to the marketing firm as part of the contract, (iii) total sum provided for marketing purposes, (iv) total amount used for marketing purposes, (v) marketing platforms used to communicate as part of the contract, (vi) policy initiative being communicated?

Q-2610² — April 29, 2024 — — With regard to the Canada Dental Benefit, to date: how many Canadians have (i) signed up, (ii) been approved, (iii) received dental care paid for through the benefit?

Q-2611² — April 29, 2024 — — With regard to the government's proposed plastics registry: (a) what is the projected cost to establish the registry and maintain it each year; (b) what is the timeline by which the government will implement the registry; and (c) did the government conduct any studies on the impact the registry will have on the price of food and other consumer products, and, if so, what are the details of each such study, including the findings and the website where the study can be found online?

Q-2612² — April 29, 2024 — — With regard to top secret security clearances provided by the government: how many employees or representatives of registered political parties currently have top secret security clearances, in total and broken down by party?

Q-2613² — April 29, 2024 — — With regard to the event named "Symposium: Building a Safe and Respectful Digital World" hosted at the Governor General's residence on April 11, 2024: (a) what were the costs associated with the event, in total and broken down by type of expenditure; (b) was this event initiated by the Governor General and her staff or officials, or by the Minister of Justice and Attorney General and his staff or officials; (c) on what dates did organizational or planning meetings take place in preparation for the event, and who was in attendance at each meeting; (d) were any government bills or initiatives highlighted during the event, and, if so, which ones; and (e) what specific action, if any, was taken by the Minister of Justice and Attorney General to ensure that the event did not put the Governor General in a partisan situation, and to stop any government legislation, initiatives or talking points from being promoted at the event?

Q-2614² — April 29, 2024 — — With regard to government engagement, association, or dealing in any other manner with social media influencers related to budget 2024 or any of the announcements leading up to the budget: (a) what are the names and handles of the influencers who were invited to (i) events on budget presentation day in Ottawa, (ii) government announcements or events in the month leading up to budget 2024; and (b) what are the amounts and details of all expenditures, in total, and broken down by influencer and type of cost the government incurred or expects to incur related to influencers, including, but not limited to, any payments being made to the influencers, travel costs, per diems, hospitality expenses, reimbursements for expenses incurred, honorariums, contracts, grants, monetary and non-monetary gifts, or any other type of incentive, financial or otherwise?

Q-2615² — April 29, 2024 — — With regard to government information about crime, broken down by year since 2016: how many suspects who were charged or deemed chargeable with homicide were on (i) bail or other type of remand, (ii) house arrest, (iii) parole, (iv) another type of community supervision, broken down by type, (v) an arrest warrant for a different crime, at the time they were charged or deemed chargeable?

Q-2616² — April 29, 2024 — — With regard to Canada's sanctions against the Russian Federation: (a) on what date was Airbus Canada granted a waiver to import titanium from the VSMPO-AVISMA Corporation; (b) which minister approved the waiver; (c) what was the rationale for the waiver; (d) who was consulted before the waiver was granted; (e) was the Ukrainian government informed before the waiver was granted, and, if so, when; (f) if the answer to (e) is negative, why not; and (g) has any other company in Canada been granted a waiver or waivers to Canada's sanctions regime against the Russian Federation since February 21, 2024, and, if so, what are the details, including the names of the companies?

Q-2617² — April 29, 2024 — — With regard to federal housing investments for Windsor, Toronto and Hamilton, since February 1, 2006, broken down by year and city: (a) how much federal funding was provided to support the construction of nonprofit or community housing and how many units were developed; (b) how much federal funding was provided to support the construction of cooperative housing and how many units were developed; and (c) how much federal funding was provided to support the construction of purpose-built rental housing and how many units were developed?

Q-2618² — April 29, 2024 — — With regard to Rent-Geared-Income (RGI) subsidies and operating subsidies funded by the Canada Mortgage and Housing Corporation (CMHC): (a) how many housing projects and units are currently receiving RGI subsidies funded by the CMHC, broken down by municipality, province or territory; (b) how many are receiving operating subsidies funded by the CMHC, broken down by municipality, province and territory; (c) is there an end or expiration date for the CMHC-funded RGI subsidies and operating subsidies for these housing projects/units and, if so, (i) what is the end date, (ii) how many units will lose the CMHC RGI subsidies broken down by (iii) municipality, province and territory, (iv) year; (d) what is the CMHC’s annual budget allocation for RGI subsidies, broken down by (i) municipality, province and territory, (ii) year since 1990; and (e) what is the CMHC’s annual budget allocation for operating subsidies, broken down by (i) municipality, province and territory, (ii) year since 1990?

Q-2619² — April 30, 2024 — — With regard to audits conducted by the Canada Revenue Agency (CRA), broken down by province or territory and fiscal year since 2015-16: (a) what is the total number of audits that determined a tax-payer had failed to withhold tax on rent paid to a non-resident landlord; (b) of the audits in (a), what is the total number of audits where (i) an adjustment resulting in more tax owing, (ii) an adjustment resulting in less tax owing, (iii) no adjustment, was made; (c) what is the total dollar value of payments received by the CRA as a result of the audits in (a); and (d) what were the total costs to the government related to 3792391 Canada Inc. v The King, 2023 TCC 37?

Q-2620² — April 30, 2024 — — With regard to federal housing investments for Vancouver Island, since February 1, 2006, broken down by year: (a) how much federal funding was provided to support the construction of non-profit or community housing and how many units were developed; (b) how much federal funding was provided to support the construction of cooperative housing and how many units were developed; and (c) how much federal funding was provided to support the construction of purpose-built rental housing and how many units were developed?

Q-2621² — April 30, 2024 — — With regard to the statement by the Minister of Justice and Attorney General of Canada in the House of Commons chamber on April 18, 2024 that, “In the budget, we have already announced that we are going to increase the maximum sentences for auto theft”, for each auto theft offence: (a) how many people have been convicted of each of the related offences since January 1, 2016, broken down by year and offence; (b) of those convicted in (a), how many offenders received the maximum sentence, broken down by year and offence; and (c) how many offenders have received the mandatory six months imprisonment for a third offence?

Q-2622² — April 30, 2024 — — With regard to government patronage, contracts and funding provided to the individuals who signed the document entitled "An Open Letter from Economists on Canadian Carbon Pricing": (a) which of the individuals who signed the document have received government contracts since November 4, 2015; (b) what are the details of all contracts in (a), including, for each, the (i) date, (ii) vendor, (iii) amount, (iv) description of the goods or services provided, (v) manner in which it was awarded (sole-sourced versus competitive bid); (c) what are the details of all grants or contributions issued to the signatories or the institutions they represent since November 4, 2015, including, for each, the (i) date, (ii) recipient, (iii) amount, (iv) purpose of the grant or contribution; and (d) which of the signatories has received an Order in Council appointment from the government or have served on any type of government advisory body since November 4, 2015, including, for each, the (i) name of the individual, (ii) body or organization for which they were appointed or served, (iii) position?

Q-2623² — April 30, 2024 — — With regard to the trip to Washington, D.C. by the Minister of Innovation, Science and Industry on April 27 and 28, 2024: (a) what was the minister's detailed itinerary on the trip; and (b) what are the details of each meeting attended by the minister on the trip, including the (i) date, (ii) time, (iii) purpose, (iv) list of attendees?

Q-2624² — April 30, 2024 — — With regard to the government's decision to decrease the amount of the carbon pricing revenues rebated for small businesses from 7% to 5%: (a) why is the government decreasing the percentages; and (b) on what date will the decrease take effect?

Q-2625² — April 30, 2024 — — With regard to Canada-wide Early Learning and Child Care Agreements, broken down by province or territory and by year, since October 1, 2019: what was the (i) total number of early learning and child care spaces available during the fiscal year, broken down by age group of child and type of setting, (ii) number of net new spaces created during the fiscal year, broken down by age group of child and type of setting, (iii) total number of inclusive spaces created or converted, broken down by age group of child and type of setting, (iv) average daily parental out-of-pocket fee for regulated child care spaces at the end of each fiscal year, (v) number of children 0 to K receiving fee subsidies, broken down by families receiving partial and full subsidies, (vi) number or proportion of child care service providers who provide services that are adapted to the needs of children with disabilities and children needing enhanced or individual supports, (vii) number and percentage of staff working in regulated child care programs who fully met the province's certification and educational requirements, (viii) annual public expenditure on training and professional development of the early childhood workforce, (ix) indicator data related to the wages of the early childhood workforce according to the categories of certification, including any wage enhancements, top-ups or supplements?

Q-2626² — April 30, 2024 — — With regard to the 2023 Canadian federal worker strike: (a) what was the total amount mistakenly paid out to striking employees; and (b) what is the amount that has not been collected back by the government?

Q-2627² — April 30, 2024 — — With regard to sole-sourced contracts entered into by the government related to products or services for ministers or their offices, including the Office of the Prime Minister, since January 1, 2019, broken down by each minister: what are the details of each such contract, including, for each, the (i) date, (ii) vendor, (iii) amount, (iv) description of goods or services?

Q-2628² — April 30, 2024 — — With regard to expenditures related to the Cabinet retreat which took place in Montréal, from January 21 to 23, 2024, including expenses incurred by the Privy Council Office as well as by other departments or agencies, and including travel expenses incurred by ministers, ministerial staff, and others: (a) what are the total expenditures related to the retreat incurred to date; (b) what is the breakdown of the expenditures by type of expense (accommodation, hospitality, audio-visual, etc.); (c) what are the details of all expenditures in excess of $1,000, including, for each, the (i) amount, (ii) vendor, (iii) description of the goods or services provided; and (d) what are the details of all travel expenses incurred by ministers and their staff, broken down by individual, including, for each, (i) the title, (ii) the amount spent on airfare, (iii) the amount spent on other transportation, (iv) the amount spent on accommodation, (v) the hotel or venue name, (vi) the amount spent on meals or per diems, (vii) other expenses, broken down by type?

Q-2629² — April 30, 2024 — — With regard to the Canadian Broadcasting Corporation (CBC): how much advertising revenue did the CBC receive from government departments, agencies, and other Crown corporations during the 2023-24 fiscal year?

Q-2630² — April 30, 2024 — — With regard to expenditures on public relations or media training, or similar type of services for ministers or their offices, including the Office of the Prime Minister, since March 1, 2022, and broken down by minister: what are the details of each such expenditure, including the (i) date of the contract, (ii) amount, (iii) vendor, (iv) individual providing the training, (v) summary of the services provided, including the type of training, (vi) person who received the training, (vii) date of the training?

Q-2631² — April 30, 2024 — — With regard to planned funding by the government related to "safe" or "safer" supply programs: how much does the government plan on spending on such programs, broken down by department, agency, and initiative in the current fiscal year and in each of the next five fiscal years?

Q-2632² — April 30, 2024 — — With regard to any arrangements the Canada Infrastructure Bank (CIB) has with banks or other financial institutions to back up their financing in the event that the CIB is dissolved: what are the details of any such agreements, or similar type of agreements that the CIB has entered into, including who the agreement is with, when it was signed, whether there is a cost to taxpayers, what collateral or guarantees are involved, and how much is being paid to each of the financial institutions?

Q-2633² — May 1, 2024 — — With regard to the Immigration, Refugees and Citizenship Canada Client Support Centre, in its Montreal offices: what is the number of (i) unilingual anglophone, (ii) bilingual, (iii) unilingual francophone, agents?

Q-2634² — May 1, 2024 — — With regard to the Royal Canadian Navy's Halifax-class frigates: (a) what is the number of (i) sea days, (ii) non-sea days, that each frigate has had for each of the last 48 months, broken down by month and by frigate; (b) what is the breakdown of the reasons for non-sea days, including the number of days each month that each frigate was not at sea for each of the reasons; and (c) what is the percentage of frigate fleet readiness each month for the last 48 months, broken down by month for the (i) total fleet, (ii) Pacific fleet, (iii) Atlantic fleet?

Q-2635² — May 1, 2024 — — With regard to the government's safe supply, safer supply and prescribed alternatives programs, broken down by year for the last two years: (a) which companies were allowed to import drugs into Canada that were to be used under the programs, broken down by drug that they were allowed to import; (b) how much of each drug was each company (i) allowed to import, (ii) importing, into Canada; and (c) what are the details of all contracts the government has had, or currently has, with companies related to providing drugs for the programs, including, for each, the (i) date, (ii) vendor, (iii) value of the contract, (iv) amount of drugs provided as part of the contract, in total and broken down by substance?

Q-2636² — May 1, 2024 — — With regard to government expenditures related to preparations for committee appearances by ministers, government officials, or representatives of any government department, agency, Crown corporation or other government entity, or for appearances by any former official, since January 1, 2019: what are the details of each expenditure, including the (i) date of the contract, (ii) vendor, (iii) description of goods or services, (iv) date of the committee appearance, (v) name and title of the individual or individuals appearing at committee, (vi) name of the committee, (vii) manner in which the contract was awarded (sole-sourced or competitive bid)?

Q-2637² — May 1, 2024 — — With regard to government dealings with Pollara Strategic Insights (PSI) since January 1, 2020: (a) what are the details of all contracts signed between government departments and agencies and PSI, including, for each, the (i) date, (ii) amount, (iii) description of goods or services, (iv) manner in which the contract was awarded (sole-sourced or competitive bid), (v) topics of research or polling covered by the contract, if applicable; (b) what are the details of each poll conducted by PSI for the government, including, for each, the (i) date, (ii) questions asked, (iii) results; and (c) what are the details of all meetings held between government officials, ministers or ministerial staff and PSI owner Don Guy, including, for each, the (i) list of attendees, (ii) date, (iii) location, (iv) purpose of the meeting?

Q-2638² — May 1, 2024 — — With regard to government dealings with economists Jim Stanford, Andrew Sharpe, Mostafa Askari, Mel Cappe, Marc Lévesque formerly of the Public Sector Pension Investment Board, Don Drummond, Kevin Milligan, Stephen Gordon, Andrew Leach, Paul Beaudry, Pierre Fortin, and Mike Moffat, since November 4, 2015: (a) which of the economists above have received government contracts; (b) what are the details of all contracts with these economists, including, for each, the (i) date, (ii) vendor, (iii) amount, (iv) description of the goods or services provided, (v) manner in which it was awarded (sole-sourced versus or competitive bid); (c) what are the details of all grants or contributions issued to these economists, including, for each, the (i) date, (ii) recipient, (iii) amount, (iv) purpose of the grant or contribution; and (d) which of these economists have received an Order in Council appointment from the government or have served on any type of government advisory body since November 4, 2015, including, for each, the (i) name of the individual, (ii) body or organization for which they were appointed or served, (iii) position, (iv) start and end dates?

Q-2639² — May 1, 2024 — — With regard to Public Services and Procurement Canada and the “mPersona“ application: (a) what was the total amount paid to the 34 employees tasked to use the “mPersona” application created by Symaiotics; (b) what was the total amount paid to Symaiotics and any other company during the application’s trials, and, if there were other companies, how much was each company paid, broken down by company; and (c) how many hours did the 34 employees work on the application?

Q-2640² — May 1, 2024 — — With regard to firearms which were prohibited as a result of the May 1, 2020, Order in Council SOR/2020-96: (a) how many have been (i) turned in, (ii) seized, (iii) confiscated, (iv) otherwise obtained by the government broken down by how it was obtained; (b) what is the breakdown of (a) by those firearms which were previously in the possession of individuals versus businesses; and (c) what is the breakdown of (a) and (b) by make and model?

Q-2641² — May 1, 2024 — — With regard to the claim on page 29 of the 2024 budget document entitled “Tax Measures: Supplementary Information,” that the federal government returns more than 90% of direct proceeds from the fuel charge to individuals through the Canada Carbon Rebate: (a) what indirect or other proceeds from the carbon tax does the government receive; (b) how much money was received by the government in the last fiscal year from each of the indirect or other proceeds listed in (a); and (c) if the government does not track how much revenue it receives in indirect or other proceeds from the carbon tax, (i) why not, (ii) why does it make claims about people benefitting from the carbon tax knowing that it does not track this data?

Q-2642² — May 1, 2024 — — With regard to Crown-Indigenous Relations and Northern Affairs Canada's Northern Abandoned Mine Reclamation Program: (a) how much has been spent to date on the Giant Mine, in total and broken down by the (i) purpose, (ii) recipient, of the funding; (b) how much is allotted to each purpose and recipient in (a), in total and broken down by (i) purpose, (ii) recipient; and (c) what are the details of all consultant contracts for the Giant Mine and the Giant Mine Oversight Board, including, for each, the (i) date, (ii) vendor, (iii) amount, (iv) description of the goods and services, (v) manner in which the contract was awarded (sole-sourced or competitive bid), (vi) start and end dates, if applicable?

Q-2643² — May 1, 2024 — — With regard to those fatalities and serious adverse events (SAEs) associated with Pfizer's and Moderna's COVID-19 mRNA-based vaccines and tracked by Health Canada (HC) and the Public Health Agency of Canada (PHAC): (a) did HC or the PHAC or any other federal agency or entity or agency contracted by the federal government detect a safety signal when examining, (i) the VAERS data from the USA, (ii) the EudraVigilance data from Europe, (iii) the Yellow Card data from England; (b) if the answer to (a) is affirmative for either (i), (ii) or (iii), what are the safety issues and how is the federal government addressing them; (c) what are the respective provincial numbers of vaccine-associated fatal and nonfatal heart attacks, strokes and other cardiovascular events recorded in Canada's vaccine surveillance program(s), between December 31, 2020 and December 31, 2023; (d) given the data from (c), has HC, the PHAC, or another federal government body such as the Canadian Institute for Health Information (CIHI) undertaken the research to determine if there has been an increase in the events described in (c) compared with their baseline values prior to the COVID-19 vaccine roll-outs; (e) what does the temporal association between the fatal or non-fatal serious adverse events in (c) and the timing of the mRNAbased vaccine roll-outs (primary series and boosters) show, per age group; (f) has the submission of any provincial health agencies' reports of vaccine-associated fatalities been denied by Canada's vaccine surveillance program(s); (g) if the answer to (f) is affirmative, how many reports of fatalities were denied by Canada's vaccine surveillance program(s) and for what reasons; (h) how many fatalities and SAEs associated with any drug or medical devices removes that item from the market; (i) how many fatalities and SAEs associated the mRNA-based vaccines will be deemed sufficient, as a threshold safety signal, to shut down the distribution of the mRNA products and what agency has established this benchmark; and (j) in consideration of cumulative reports of fatalities and SAEs during Pfizer's 3-month post-marketing phase, and in Canada and other jurisdictions around the world associated with the mRNA products, why was this vaccination program permitted to continue and who made that decision?

Q-2644² — May 1, 2024 — — With regard to the review by Health Canada (HC), the Public Health Agency of Canada (PHAC), or the National Advisory Committee on Immunization, of a pre-print study posted on October 15, 2023 of which six authors are associated with the US Food and Drug Administration that found "a new signal was detected for seizures-convulsions after BNT162b2 (2-4 years) and mRNA1273 COVID-19 vaccinations (2-5 years),": (a) which federal health agency, organization, committee or department(s) or outsourced contracted firm is responsible for reviewing or identifying studies such as the pre-print titled "Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID- 19 Vaccines in US Children Aged six months to 17 years;"; (b) has any federal health agency, organization, committee, department(s) or outsourced contracted firm reviewed or been made aware of the forementioned study or learned about the new safety signal of seizures/convulsions among children following monovalent COVID-19 vaccine; (c) if the answer to (b) is affirmative, has HC or any federal health agency, organization or committee issued any statement to the Canadian public or any communication to the provinces or the medical community to create awareness of this new safety signal; (d) if the answer to (c) is affirmative, what was the statement or communication provided; (e) if the answer to (c) is negative, why not; (f) how many episodes of seizures-convulsions have been reported in children under 17 years in Canadian Adverse Events following Immunization Surveillance System records, from (i) May 1, 2021 to April 30, 2023, (ii) May 1, 2018 to April 30, 2020; (g) what provincial and territory data is the federal government relying upon to monitor risk of seizures and convulsions in this cohort in real time; (h) how far out is the government monitoring this data (e.g. 28 days post-vaccine, up to 3 months, 6 months, 12 months, beyond 12 months post-COVID-19 immunization); (i) what are the Canadian government's threshold values for marking the likelihood of a vaccine serious adverse event as transitioning from an extremely rare, to a rare occurrence, and from a rare to a common occurrence; (j) what is the threshold whereby a safety signal of seizures or convulsions would shut down the mRNA vaccine program in children under the age of 17 years; (k) why are children's seizures-convulsions not listed on HC's webpage denoted to children's side-effects which was last updated on October 27, 2023; (l) with real-time monitoring, what other safety signals has HC, the PHAC or any other federal agency or department discovered post-mRNA vaccine injection for (i) children under age 5 years, (ii) children 6-17 years, (iii) persons 18-25 years, (iv) persons 26-35 years; (m) is HC receiving any data directly from provincial datasets to monitor increased usage of provincial health systems by Canadian children post-vaccination; (n) has any federal health agency or entity such as the Canadian Institute for Health Information or outsourced contractor tracked the number of episodes of myocarditis and pericarditis in young persons under the age of 35, post-vaccination, using billing or ICD-10 data from physicians and hospitals across Canada both before and after the COVID-19 injections had commenced; (o) if the answer to (n) is affirmative, (i) for what period of time post-immunization are they tracked, (ii) is the rate of myocarditis and pericarditis in persons under 35 years following the roll-out of the COVID-19 mRNA vaccines greater or less than the baseline rates of myocarditis and pericarditis from 2016-2019; (p) if there were deviations from the baseline found in (o)(ii), by how much did this occur and by which method has the determination of any difference, or lack thereof, been made; (q) if the answer to (n) is negative, why is this data not being tracked; and (r) when examining the risk-of-harm to benefit ratio of the COVID-19 mRNA products and when considering the combination of serious adverse events such as seizures-convulsions, myocarditis and pericarditis in young persons, what is the combined threshold of serious adverse events by which mRNA products would no longer be available to (i) children under the age of 5 years, (ii) children 6-17 years old, (iii) persons 18-25 years old, (iv) persons 26-35 years old, and who determines these thresholds, when, and based on what data?

Q-2645² — May 1, 2024 — — With regard to Correctional Service Canada, broken down by year since 2008: what is the capacity of federal institutions and the number of those incarcerated (i) in total, (ii) by region, (iii) by correctional institution?

Q-2646² — May 1, 2024 — — With regard to bonuses paid out at VIA HFR – Dedicated Project Office in the 2023-24 fiscal year: (a) what was the amount paid out in bonuses (i) in total, (ii) to executives; (b) how many individuals received payments; (c) what percentage of officials that received bonuses were (i) at or above executive level or equivalent, (ii) below the executive level or equivalent; (d) what is the average amount of payments (i) at or above executive level or equivalent, (ii) below the executive level of equivalent; and (e) what is the highest amount of payment?

Q-2647² — May 1, 2024 — — With regard to end-of-life marine vessel decommissioning and recycling, colloquially known as Shipbreaking, since January 1, 2016, broken down by year: (a) how many oversea tows of retired laker or coastal ships did Transport Canada approve; (b) how many of the oversea tows of retired lakers or costal ships that Transport Canada approved changed their final destination once in international waters; and (c) how many retired laker or costal ships were recycled in Canada?

Q-2648² — May 1, 2024 — — With regard to Health Canada (HC), the Public Health Agency of Canada (PHAC) and the reporting processes of adverse events following immunization (AEFI) and the implementation of the Brighton Collaboration Case Definitions of AEFIs: (a) in what ways does HC’s Canada Vigilance Program (CVP) differ from the PHAC’s Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) reporting system; (b) what purpose does it serve for Canada to have two reporting systems; (c) how, if at all, is the CVP and CAEFISS data amalgamated; (d) regarding HC’s relationship to the Brighton Collaboration (BC), (i) does one exist, and, if so, when did HC or the PHAC start using the BC criteria as a requirement for AEFI recognition, (ii) what is the BC’s purpose in the vaccine space in Canada; (e) regarding the implementation of the BC criteria, (i) when was it communicated to health care practitioners, (ii) how was it communicated; (f) were there any definitions of AEFIs that were changed after January 1, 2019 by (i) the BC, (ii) HC, (iii) the PHAC, (iv) the National Advisory Committee on Immunization; (g) if the answer to (f) is affirmative, (i) which ones were changed and by which agency, (ii) how were they changed, (iii) why were they changed; (h) is HC aware of the entities, such as the Coalition for Epidemic Preparedness Innovations, which partner with the BC; (i) if the answer to (h) is affirmative, what are those entities and corporations along with their inherent conflicts of interest (COI) in the vaccine space; (j) what or who are the other funding and non-funding entities who partner with the BC; (k) is HC aware of those individuals who constitute the BC’s Board of Directors and those who have been trained at the BC, including the members of the Advisory Committee on Causality Assessment; (l) if the answer to (k) is affirmative, (i) what percentage of those individuals are working, have worked, or have consulted for a pharmaceutical company, (ii) how many work in Canada; (m) of the individuals identified in (l) as Canadians, (i) what are their names, (ii) what are their conflicts of interest, (iii) what positions do they hold in other entities; (n) how much does the Government of Canada, and any entity related to the Government of Canada, provide monetarily to the BC; and (o) is the BC associated, either directly or indirectly, with any vaccine manufacturers or related organizations?

Q-2649² — May 1, 2024 — — With regard to the Canada Border Service Agency's (CBSA) releasing detainees, who would otherwise be held in custody pending deportation, due to a lack of detention capacity: (a) how long has the government known about the problem; (b) how many meetings has the government had on this issue; (c) what steps has the government taken to address this issue; and (d) how many detainees does CBSA project will have to be released due to lack of capacity?

Q-2650² — May 1, 2024 — — With regard to the government’s approach to the Chinese state owned CRRC Corporation Limited: (a) has the government identified any threats to national security from CRRC, and, if so, what are the details of each; (b) has the government identified any safety or performance issues with the operation of CRRC rolling stock in Canada, and, if so, what are the details of each; (c) since January 1, 2016, and broken down by year, how many projects involving CRRC have been approved by Transport Canada; and (d) since Canada joined the Asian Infrastructure Bank on March 19, 2018, is the government aware of (i) any CRRC projects that received funding from the Asian Infrastructure Bank, (ii) any other funds received by CRRC from the Asian Infrastructure Bank, and, if so, what are the details of each?

Q-2651² — May 2, 2024 — — With regard to Health Canada (HC) and the initial Pfizer-BioNTech mRNA product and approval process thereof: (a) did HC ask Pfizer to conduct genotoxicity studies to rule out insertional mutagenesis with DNA contamination; (b) if the answer to (a) is negative, why not; (c) what are the dangers with respect to insertional mutagenesis; (d) in the context of the mRNA vaccine, what is the purpose of the lipid nanoparticle (LNP) delivery system; (e) in the context of the mRNA vaccine manufacturing process, (i) what is the purpose of the SV40 enhancer-promoter-ori sequence, (ii) does it include a 72 base pair Nuclear Targeting Sequences (NTS), (iii) if the answer to (ii) is affirmative, what is the purpose of an NTS; (f) with regard to the plasmid map used in the production of the modified mRNA, (i) on what date did the manufacturer provide the map to HC, (ii) what gene annotation was provided; (g) in relation to (f), did the map contain an SV40 promoter-enhancer sequence and a reverse open reading frame; (h) if no plasmid map was received, why did HC not ask for one; (i) according to the response to Order Paper question Q-2266, “There are strict limits and controls for the presence of these residual fragments to ensure that there is no effect on the safety or effectiveness of the vaccine,” as part of the residual DNA testing and measurement, (i) what quantity of DNA fragments and SV40 enhancer-promoter fragments per dose were found in the Pfizer product, (ii) who provided the data to HC, (iii) when was this data provided to HC, (iv) is HC aware that the EMA reported a very large variance with respect to the residual DNA levels in the bulk mRNA and that the SV40 enhancer in the promotor sequence is 72 base pairs, (v) if the answers to (i) and (iv) are affirmative, what was HC’s appraisal of this information, (vi) what analytical techniques did the manufacturer rely upon to quantify the amount of RNA and the amount of DNA, (vii) do these quantities meet the “strict limits and controls for the presence of these residual fragments” and what are those limits; (j) as part of HC’s requirements for lot release testing, has HC independently confirmed the quantity of residual DNA and SV40 sequences in the Pfizer-BioNTech product; (k) if the answer to (j) is affirmative, (i) which laboratory and chief scientist provided this independent testing, (ii) what were the amounts recorded, (iii) were these different than those amounts provided by the manufacturer; (l) if the answer to (j) is negative, why was independent testing not completed; (m) is HC aware that Pfizer deliberately removed the SV40 enhancer sequence when reporting the annotated plasmid; and (n) according to HC's response to Order Paper question Q-2266, “The SV40 promoter enhancer sequence… is inactive, has no functional role, and was measured to be consistently below the limit," (i) who provided HC with this assessment, (ii) is there evidence that the SV40 promoter binds to the P53 tumor suppressor gene and affects DNA repair mechanisms, (iii) if the answer to (ii) is affirmative, what are the risks to the health of Canadians as a result?

Q-2652² — May 2, 2024 — — With regard to Health Canada’s standards for safety and efficacy for the COVID-19 vaccines: (a) have any COVID-19 vaccines met the requirements of Section C.08.001(2) of the Food and Drug Regulations (2)(g) and (2)(h) for safety and efficacy; (b) has any COVID-19 designated drug or vaccine, approved under Section C.08.001(2.1) of the Food and Drug Regulations, subsequently met the standard for safety and efficacy as delineated in subsection (2)(g) and (2)(h) of Section C.08.001(2); (c) if the answer to (b) is negative, why not; (d) if a COVID-19 designated vaccine has not met (2)(g) and (2)(h) of C.08.001(2), which requires the sponsor to establish safety and efficacy, can the use of the terms “safe and effective” be applied to these vaccines; (e) if the answer to (d) is affirmative, what is the rationale; (f) with regard to the portal on the approval of COVID-19 vaccines for Comirnaty and available information for COMIRNATY - Submission control number 252736 on the Government of Canada's website, is the information for 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods available to the public under the transparency initiatives; (g) if the answer to (f) is negative, why not; (h) as the mRNA vaccines represent a new manufacturing platform, do they meet the requirements of Section C.04.015 of the Food and Drug Regulations; (i) if the answer to (h) is negative, why not; (j) have the Pfizer-BioNTech and Moderna vaccines been assigned to Group 2 Lot Evaluation Group as part of the Lot Release Program; and (k) if the answer to (j) is negative, why not?

Q-2653² — May 2, 2024 — — With regard to Report 5 (2024) of the Commissioner of the Environment and Sustainable Development to the Parliament of Canada: (a) how much has the Department of Agriculture and Agri-Food spent in the past five years on developing a climate change mitigation strategy; (b) how many employees were or are assigned to work on the strategy; and (c) how was the money spent, broken down by initiative?

Q-2654² — May 2, 2024 — — With regard to the Dairy Innovation and Investment Fund: (a) how many applications did the program receive; (b) how many of those applications were accepted; (c) how much of the total program funding was allotted to applicants; and (d) how much funding has been released to date, broken down by province?

Q-2655² — May 2, 2024 — — With regard to Immigration, Refugees and Citizenship Canada (IRCC) and the temporary public policy creating permanent resident pathways for Hong Kong residents since 2021, broken down by year: (a) how many individuals of Hong Kong origin have immigrated to Canada under the permanent residency program, broken down by (i) economic class migration, (ii) the family reunification program, (iii) the refugees and protected persons class, (iv) the "humanitarian and other" class, broken down by individualized stream; (b) how many individuals of Hong Kong origin have applied for permanent residency on "humanitarian and compassionate grounds" separately from the temporary public policy permanent residency pathways since 2021; (c) with regard to the temporary public policy, what is the breakdown of the application numbers since 2021 for (i) Stream A, (ii) Stream B, broken down by PR category; (d) of the figures in (c), how many applications were (i) approved, (ii) rejected, (iii) under review; (e) of the rejections in (d), what are the categorized reasons for rejecting the application, broken down by number; (f) of the cases under review and rejections in (c), what is the breakdown of the applications by (i) individual applications, (ii) family applications; and (g) of the approvals in (c), how many were tied to existing departmental quotas for the temporary public policy or the department's annual planned admission range per IRCC's annual report for permanent residency admissions under (i) economic class migration, (ii) the family reunification program, (iii) the refugees and protected persons class, (iv) the "humanitarian and other" class?

Q-2656² — May 2, 2024 — — With regard to Immigration, Refugees and Citizenship Canada (IRCC) and the open work permit pathway under a temporary public policy for Hong Kong residents: (a) what is the number of applications received by individuals of Hong Kong origin with "HKPPTR" inputted for the job title since the program was instituted in 2021; (b) of the applications in (a), how many were (i) accepted, (ii) rejected, (iii) under review; (c) of the rejections in (b), what is the breakdown of rejections by the location of the IRCC office or processing center; and (d) how many applications were rejected based on the lack of labour market impact assessment?

Q-2657² — May 2, 2024 — — With regard to the Immigration and Refugee Board of Canada (IRB): (a) what is the total number of adjudicators at the Refugee Protection Division; (b) of the adjudicators in (a), how many have postsecondary degrees, broken down by (i) office, (ii) type of degree; (c) of the adjudicators in (a), how many have previous tribunal experience; (d) of the adjudicators with prior tribunal experience, (i) what office do they work in, (ii) how many years of experience do they have, (iii) what year were they hired; (e) of the adjudicators in (a), how many have prior public service experience; (f) for each adjudicator with prior public service experience, (i) what office do they work in, (ii) how many years of experience do they have, (iii) what year were they hired; and (g) what was the essential qualification criteria required to be an adjudicator at the IRB in (i) 2011, (ii) 2012, (iii) 2015, (iv) 2020, (v) August 2021, (vi) November 2021, (vii) 2023?

Q-2658² — May 2, 2024 — — With regard to the 2024 budget documents: what are the expenditures incurred to date related to the documents, in total and broken down by (i) consulting costs, (ii) publishing costs, (iii) printing costs, (iv) design costs, including graphic design, (v) writing costs, (vi) marketing costs, (vii) any other costs not reflected in the previous categories?

Q-2659² — May 2, 2024 — — With regard to Section 5.25 of the Commissioner of the Environment and Sustainable Development's report entitled "Agriculture and Climate Change Mitigation - Agriculture and Agri-Food Canada": how does the government plan to meet its 3.5 Mt CO₂ eq fertilizer emission reduction target despite the shortfall stated by the Commissioner of the Environment and Sustainable Development in the aforementioned report?

Q-2660² — May 2, 2024 — — With regard to Section 5.24 of the Commissioner of the Environment and Sustainable Development's report entitled "Agriculture and Climate Change Mitigation - Agriculture and Agri-Food Canada": to achieve the fertilizer emission reduction targets, what voluntary agreements have been made between Agriculture and Agri-Food Canada and with fertilizer manufacturers, agricultural stakeholders, provinces, and farmers?

Q-2661² — May 2, 2024 — — With regard to Agriculture and Agri-Food Canada since January 2024: what is Agriculture and Agri-Food Canada's progress on developing a strategy to guide its climate change mitigation programs and activities?

Q-2662² — May 2, 2024 — — With regard to Exhibit 5.1 of the Commissioner of the Environment and Sustainable Development's report entitled "Agriculture and Climate Change Mitigation - Agriculture and Agri-Food Canada": (a) what was the methodology in determining the emissions of crop production; (b) what data gathering techniques were utilized; and (c) what were the earliest and latest data points that were used?

Q-2663² — May 2, 2024 — — With regard to Exhibit 5.1 of the Commissioner of the Environment and Sustainable Development's report entitled "Agriculture and Climate Change Mitigation - Agriculture and Agri-Food Canada": (a) what was the methodology in determining the emissions of animal production; (b) what data gathering techniques were used; (c) what were the earliest and latest data points that were used; (d) can the data be broken down by animal and by sector (e.g. beef, dairy, poultry); and (e) were meat processing facilities included in this data?

Q-2664² — May 2, 2024 — — With regard to Bill S-14, An Act to amend the Canada National Parks Act, the Canada National Marine Conservation Areas Act, the Rouge National Urban Park Act, and the National Parks of Canada Fishing Regulations: did any government department or agency do any consultations related to the proposed measures in the bill, and, if so, (i) who were the groups and people that were consulted, (ii) how much money was spent on the consultation process, (iii) what were the results or recommendations of the consultations, (iv) when were the consultations conducted, (v) how were the consultations conducted?

Q-2665² — May 2, 2024 — — With regard to Health Canada's (HC) review into the presence of SV40 and other DNA elements in the Pfizer COVID-19 vaccine: (a) what were HC’s concerns regarding "SV40 enhancer-promoter sequence and other non-essential sequences in Pfizer's plasmid for their COVID-19 vaccines" as noted in email correspondences between HC, European Medicines Agency (EMA) and the Food and Drug Administration officials in August 2023 prior to an ad-hoc Cluster meeting held on August 24, 2023; (b) what did HC ask of Pfizer to mitigate the concerns in (a), and what was Pfizer's response; (c) did HC's experts review Kevin McKernan's et al. study entitled “Sequencing of bivalent Moderna and Pfizer mRNA Vaccines reveals Nanogram to Microgram Quantities of Expression Vector dsDNA per Dose”; (d) if the answer to (c) is affirmative, (i) what were HC's summary conclusions, (ii) how did HC respond to those conclusions; (e) is HC still of the position that "there is no peer-reviewed scientific literature suggesting that the SV40 promoter-enhancer itself or the other non-functional elements pose a risk to human health"; (f) if the answer to (e) is negative, what key peer-reviewed scientific literature did HC consider noteworthy; (g) is HC aware of the ability of the SV40 promoter-enhancer to bind to P53 as demonstrated by Drayman et al.; (h) if the answer to (g) is affirmative, (i) was the risk communicated to Pfizer, (ii) what was Pfizer's response; (i) if the answer to (g) is negative, will HC perform a risk analysis to human health; (j) is HC aware of the ability of the SV40 enhancer to act as a nuclear targeting sequence as demonstrated by Dean DA, Dean BS, Muller S, Smith LC. in their study entitled “Sequence Requirements for Plasmid Nuclear Import”; (k) if the answer to (j) is affirmative, was the risk communicated to Pfizer and a response requested; (I) if the answer to (j) is negative, will HC perform an independent risk analysis to human health; (m) if Pfizer's vaccine did not contain unsafe or unexpected plasmid sequences, such as SV40 promoter-enhancer, then why, on August 29, 2023, did Michael Wall state in an email to Tong Wu, "Health Canada will continue to work with international regulatory partners to achieve harmonisation regarding removal of these sequence elements from the plasmid for future strain changes"; (n) what are the "sequence elements" to which Michael Wall was referring; (o) regarding an email, on October 12, 2023, from an EMA colleague to Dr. Dean Smith at HC, which stated "We are going to discuss the matter of SV40 with Pfizer-BioNtech as well as these alleged high level of DNA in vaccines coming from these external parties. Have you taken any action? What would be your perspective?", (i) what action was taken or will be taken to address the "alleged high level of DNA" referenced in the email, (ii) has any action been taken to date, and, if so, what; (p) has HC informed (i) the Public Health Agency of Canada, (ii) Dr. Howard Njoo, (iii) Dr. Theresa Tam, (iv) Dr. Supriya Sharma, (v) the National Advisory Committee on Immunization, (vi) any or all of the provincial or territorial Chief Medical Officers, of the presence of the SV40 enhancer-promoter and DNA fragments; (q) if the answers to (p)(i) to (p)(vi) are affirmative, what were their individual responses; (r) if the answers to (p)(i) to (p)(vi) are negative, why or why not; (s) what risk assessment did HC perform to determine that SV40 promoter-enhancer is safe in an mRNA vaccine within the unique LNP delivery system; (t) what other Canadian vaccines contain SV40 promoter-enhancer sequence; and (u) what is HC's policy about SV40 promoter-enhancer being in any vaccine product?

Q-2666² — May 2, 2024 — — With regard to the government's appointment of Catherine Blewett to be Secretary of the Treasury Board, effective February 6, 2024: (a) since February 6, 2024, broken down by month, how many days did the Secretary work in person at the Treasury Board Secretariat's main office at 90 Elgin Street in Ottawa; and (b) is the Secretary exempt from the government's requirement that employees are to work in the office for at least two days per week?

Q-2667² — May 2, 2024 — — With regard to Exhibit 5.8 of the Commissioner of the Environment and Sustainable Development's report entitled "Agriculture and Climate Change Mitigation-Agriculture and Agri-Food Canada" and the performance targets related to climate change mitigation in place for the Agricultural Clean Technology program: (a) what were the 193 new technologies adopted based on 141 performance reports; (b) what did the performance reports say about the adoption of these technologies; and (c) what were the 352 approved projects based on 141 performance reports?

Q-2668² — May 2, 2024 — — With regard to Health Canada's (HC) signing of the contract with Pfizer on October 26, 2020, and the subsequent release of the Pfizer mRNA COVID-19 vaccine to the Canadian public: (a) was HC aware of a presentation made to the Vaccines and Related Biological Products Advisory Committee on October 22, 2020, where Dr. Steve Anderson at the US Food and Drug Administration's Center for Biologics Evaluation and Research, presented "Plans for Monitoring COVID-19 Vaccine Safety and Effectiveness"; (b) if the answer to (a) is affirmative, did HC review the presentation deck, specifically slide #16, which identified a working list of 22 "possible adverse event outcomes", including acute myocardial infarction, stroke, myocarditis, pericarditis and death; (c) if the answer to (a) is negative, at what point did HC become aware of this presentation material or these serious adverse events of special interest; (d) once HC was in possession of this information, where and when did HC publish this list of 22 "possible adverse event outcomes" for the purpose of informing (i) the general public, (ii) medical physicians and hospitals, (iii) the media; (e) how did HC plan to independently and actively monitor these 22 "possible adverse event outcomes"; (f) did the initial Pfizer monograph posted on HC's website on December 9, 2020, and the ones posted thereafter identify any of these 22 "possible adverse event outcomes"; (g) when Pfizer vaccines were first being administered in early 2021, did HC require the sponsor to include a package insert in each mRNA vaccine vial containing a fully printed monograph of the product's ingredients and side effects including the identified 22 "possible adverse event outcomes" for both the consumer and the health professional to ensure full, informed consent; (h) if the answer to (g) is negative, (i) why was this not required, (ii) how was full, informed consent achieved at the time of vaccination; (i) did HC plan to actively monitor and publish the 1,291 "serious adverse events (SAEs) of special interest" which were contained in the Appendix of Pfizer's report of April 30, 2021, entitled "5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021" to ensure medical awareness of these potential SAEs; (j) if the answer to (i) is affirmative, (i) how were the SAEs monitored, (ii) what information was gathered; and (k) if the answer to (i) is negative, why are the 1,291 SAEs of special interest being monitored by the US Food and Drug Administration and not by HC?

Q-2669² — May 2, 2024 — — With regard to the post-market surveillance used by Health Canada (HC) to monitor for safety concerns regarding the novel COVID-19 vaccine products: (a) have HC, the Public Health Agency of Canada (PHAC), Statistics Canada or any other federal agency or entity, department, or third-party agency used databases such as the Institute for Clinical Evaluative Sciences, the Ontario Health Data Platform or any other databases that collect realtime data to determine an individual's date of medical diagnoses, including death; (b) if the answer to (a) is affirmative, what are the anonymized individual results for the following new onset diagnoses, from December 1, 2020, to the present date, cross referenced with the date of receipt of COVID- 19 vaccine, the age by 5-year increments, the gender, and the province or territory of residence, (i) cerebral infraction, (ii) cerebral hemorrhage, (iii) sudden infant death syndrome, (iv) seizure, (v) acute myocarditis, (vi) pericarditis, (vii) transverse myelitis, (viii) miscarriage, (ix) Bell's palsy, (x) pancreatic cancer, (xi) esophageal cancer, (xii) anaphylaxis, (xiii) myocardial infraction, (xiv) breast cancer, (xv) pulmonary embolism, (xvi) deep vein thrombosis, (xvii) thrombocytopenia, (xviii) pulmonary hypertension (xix) lymphoma, (xx) ruptured aortic aneurysm, (xxi) cellulitis, (xxii) Guillain Barre syndrome, (xxiii) stillbirth, (xxiv) encephalopathy due to vaccination, (xxv) encephalopathy, (xxvi) sudden death, (xxvii) preeclampsia, (xxviii) premature birth, (xxix) multiple sclerosis, (xxx) hysterectomy, (xxxi) vasculitis; (c) what are the quarterly incidence rates of the diagnoses in (b) categorized by (i) age with 5-year increments, (ii) gender, (iii) province or territory of residence from January 1, 2014, to November 30, 2020; (d) if the answer to (a) is negative, what are the quarterly incidence rates of the diagnosis in (b) from December 1, 2020, to the present day, categorized by (i) age with 5-year increments, (ii) gender, (iii) province or territory of residence; (e) if the answer to (a) is affirmative, has this data been used to compare rates of medical diagnosis between never COVID-19 vaccinated individuals and others based on the number of COVID-19 injections received; (f) if the answer to (a) is affirmative, has this data been used to determine the length of time between receipt of a COVID-19 vaccine and the medical diagnosis or death, and, if so, what are the ranges of time; (g) if the answer to (a) is affirmative, will the raw data be released to independent researchers; (h) if the answer to (a) is negative, will the government make the raw anonymized data public; (i) if the answer to (a) is negative, what plans are either in place or planned to complete such an analysis in order to validate adverse event reporting systems that may be outdated for the COVID-19 vaccine products; (j) have there been any communications from or between HC, the PHAC, Statistics Canada, or any other federal agencies or their representatives about the Institute for Clinical Evaluative Sciences, the Ontario Health Data Platform, or any other similar database sources that capture receipt of COVID-19 vaccine(s) or booster(s) and clinical outcomes to monitor for safety signals; (k) if the answer to (j) is affirmative, which government agencies or out-sourced third parties were involved, and, for each, (i) what are the communications, (ii) who directed these communications, (iii) what were the dates of these communications, (iv) what was included in these communications, (v) what were the conclusions of these communications?

Q-2670² — May 2, 2024 — — With respect to Health Canada's (HC) review into the presence of SV40 and other DNA elements in the Pfizer COVID-19 vaccine: (a) in July 2023, what was the basis for an Issue Analysis Summary (IAS) for the SV40 promoter agreed to by Ors Co Pham, Tong Wu and Michael Wall; (b) in July 2023, what was the rationale for HC to submit #1 Clarifax request to Pfizer and (i) what was the outcome of this request, (ii) did the response from the sponsor to #1 Quality Clarifax address all of HC's questions and concerns, and, if negative, what was missing, (iii) did Pfizer provide a complete justification for the SV40 sequences, (iv) did Pfizer provide an updated fully annotated table of functional elements of the plasmid, (v) did Pfizer include non-functional elements of the plasmid in the annotated table specifically addressing any unexpected open reading frames and other sequence elements, (vi) if the answer to (iii), (iv) and (v) is affirmative, what were the results, (vii) if the answer to (iii), (iv) and (v) is negative, what was HC's response; (c) with respect to the quantitative assay used to measure the residual DNA in order to confirm the presence of the SV40 promoter-enhancer, did HC confirm with Pfizer (i) the amplicon size used, (ii) the appropriateness of the primers used; (d) if the answer to (c) is affirmative, what was Pfizer's response; (e) if the answer to (c) is negative, has HC independently verified the total amounts of residual DNA, the appropriateness of the primers, and the amplicon size used by Pfizer to measure the residual DNA in the XBB.1.5 vials; (f) with respect to Pfizer's response in #1, #2 and #3 Quality Clarifaxes, did Pfizer provide the requested information on the fragment size analysis by December 1, 2023; (g) if the answer to (f) is affirmative, what were the results; (h) if the answer to (f) is negative, what was HC's response; (i) concerning the residual plasmid DNA in the drug substance, (i) did Pfizer provide the requested information on the characterization of residual circular DNA plasmid by December 1, 2023, (ii) did Pfizer provide the requested information on the risk of replication in bacterial cells by December 1, 2023, (iii) did HC at any time request information on the risk of replication in mammalian cells; (j) if the answer to (i)(i), (i)(ii) and (i)(iii) is affirmative, what were the results; (k) if the answer to (i)(i), (i)(ii), and (i)(iii) is negative, what was HC's response; (I) did HC request that Pfizer repeat the analyses for fragment size distribution and residual DNA for any of Pfizer COVID-19 vaccines (i.e., original or bivalent); (m) if the answer to (l) is affirmative, what were the findings; (n) if the answer to (l) is negative, why not; (o) did HC independently verify the quantity of residual DNA, the size distribution and the presence of SV40 sequences in the XBB.1.5. vaccine, or any other COVID-19 vaccine submitted by Pfizer for review; (p) at any time, did Pfizer ever suggest that the regulatory sequence elements in question were functional with respect to the manufacturing process, and, if so, what was the function; (q) at any time, did Plizer ever suggest that regulatory sequence elements in question were functional following inoculation into humans; and (r) if the answer to (p) is affirmative, what and when did Pfizer inform HC?

Q-2671² — May 2, 2024 — — With regard to the arrangements and travel costs for all government press briefings and pre-budget announcements in the lead-up to the tabling of the federal budget and to highlight the measures to be contained in the budget: what were the expenses and costs incurred from March 4, 2024, to April 16, 2024, the day of the budget speech, broken down by type of announcement, by date, by location and by the ministers, parliamentary secretaries and political staff present?

Q-2672² — May 2, 2024 — — With respect to Canada’s Vaccine Injury Support Program (VISP): (a) how many claims have been filed to the program from December 8, 2020, to present day, broken down by age group; (b) how many of those claims have been approved, broken down by age group; (c) of the approved claims, what have been the diagnoses and their frequencies, broken down by age group, date approved, and the corresponding COVID-19 vaccines that were administered; (d) of the approved claims, what are the percentages of Canadians who received (i) the AstraZeneca COVID-19 vaccine, (ii) the J&J COVID-19 vaccine, (iii) any COVID-19 vaccine produced by Pfizer-BioNTech, (iv) any COVID-19 vaccine produced by Moderna, (v) a combination of COVID-19 vaccines; (e) how many persons have received compensation to date through the VISP; (f) what is the total compensation to date given to vaccine-injured Canadians; (g) what is the age of the youngest person who received funding support approval through the VISP, and their associated diagnosis; (h) for all death claims, (i) what is the total number of death claims that have been filed to VISP, (ii) of the total, what have been the underlying causes of death, aside from the vaccine and their frequencies, (iii) how many filed death claims have been approved by the VISP and their corresponding diagnosis and vaccine status; (i) did the VISP require autopsies prior to approving a death claim; (j) if the answer to (i) is affirmative, what immunohistochemistry requirements does the VISP specify for these autopsies; (k) when denied, how many persons have appealed their claim and how many have been successful; (l) regarding the determination of causality of the adverse event in relation to a COVID-19 vaccine, (i) what is the standard criteria, (ii) does the Medical Review Board take into consideration the Bradford Hill criteria; (m) what are the professional qualifications of each member on the Medical Review Board; and (n) who are the professionals on the Medical Review Board?

Q-2673² — May 2, 2024 — — With regard to the COVID-19 Therapeutics Task Force (TTF) who oversaw submissions for grant funding from Innovation, Science and Economic Development Canada (ISED)’s Strategic Innovation Fund: (a) in total, how many projects were considered for funding; (b) with respect to the projects which were funded, (i) how many received funding, (ii) how much funding was allocated per project, (iii) which drugs were being investigated per each approved project, (iv) what was the total amount of funding granted for the approved projects; (c) with regard to the projects which were not approved for funding, what recommendations were made to them; (d) with regard to the therapeutics which were recommended for purchase, (i) what were these therapeutics, (ii) were these therapeutics purchased, (iii) what was the implementation plan, (iv) if there was no plan, why not; (e) were the drugs Ivermectin or Hydroxychloroquine considered by the TFF; (f) if the answer to (e) is affirmative, what were their recommendations and how did they arrive at them; (g) who were the members of the TTF; (h) were any of the members pharmacists, pharmacologists, or toxicologists; (i) what were the members' conflicts of interest; (j) did any of the members withdraw from the task force prior to its conclusion; (k) if the answer to (j) is affirmative, who left early and why; (l) regarding the document entitled “HEALTH CANADA/ PUBLIC HEALTH AGENCY OF CANADA MEMORANDUM TO THE MINISTER OF HEALTH, Meeting with the COVID-19 Therapeutics Task Force” dated February 24, 2021, and signed by the President of the Public Health Agency of Canada and the Deputy Minister of Health, which reads that “At the previous meeting TTF members expressed concern that their mandate was ending. TTF members were specifically concerned about what they felt was insufficient attention to therapeutics, failures of implementation, and the need to be forward looking for surveillance of upcoming therapeutic opportunities. It is expected that TTF members will raise these concerns to you”, (i) what concerns were raised to the signee, (ii) what documents were provided with respect to expressing those concerns; and (m) when and why was the TTF mandate ended?

Q-2674² — May 2, 2024 — — With regard to federal housing investments in Edmonton, since February 1, 2006, broken down by year: (a) how much federal funding was provided to support the construction of nonprofit or community housing and how many units were developed; (b) how much federal funding was provided to support the construction of cooperative housing and how many units were developed; and (c) how much federal funding was provided to support the construction of purpose-built rental housing and how many units were developed?

Q-2675² — May 3, 2024 — — With regard to the government’s announcement on August 12, 2021 to invest $1.44 billion into Telesat’s advanced low Earth orbit (LEO) satellite constellation, Telesat Lightspeed: (a) what are the details of government purchases or sales of Telesat equity or shares since the announcement, including, for each, the (i) date, (ii) total price or amount, (iii) type of transaction (bought or sold), (iv) number of shares or percentage of equity, (v) share price, if applicable; and (b) what is the government’s current equity stake in Telesat in terms of value, percentage of equity, and number of shares?

Q-2676² — May 3, 2024 — — With regard to the Court Challenges Program: (a) how much money has been delivered through the program in each of the last five years; (b) who has received money through the program, and how much was received; and (c) if the government refuses to answer (b) citing solicitor-client privilege, what is the government's rationale given that it is neither the solicitor nor the client in many of the related court cases?

Q-2677² — May 3, 2024 — — With regard to federal infrastructure funding, since January 1, 2016, broken down by year: (a) how much money has been distributed for infrastructure projects under the (i) Rural Transit Solutions Fund, (ii) Zero Emission Transit Fund, (iii) Active Transportation Fund, (iv) Green and Inclusive Community Buildings Program, (v) Natural Infrastructure Fund, (vi) Canada Healthy Communities Initiative; (b) what are the details of all projects in (a), including, for each, (i) the project description, (ii) the date of the funding announcement, (iii) the amount of funding originally announced, (iv) the amount of funding distributed to date, (v) the date the funding was transferred to the recipient, (vi) the recipient of the funding, (vii) the current status of the project, (viii) the project location, (ix) whether the location of the project is a Census Metropolitan Area or Census Agglomeration, (x) the original projected completion date for the project, (xi) the actual completion date for the project, if applicable, (xii) the current projected completion date for the project, (xiii) the reason for the project delay, if applicable; and (c) what are the details of any infrastructure funding which was announced, but for which the related project was later cancelled, including, for each, the (i) project name and description, (ii) project location, (iii) amount of funding originally announced, (iv) amount of funding transferred to the recipient, (v) date of the cancellation, (vi) reason for the cancellation?

Q-2678² — May 3, 2024 — — With regard to the Disability Tax Credit (DTC), broken down by fiscal year from 2015-16 to 2023-24: (a) what is the total number of people that applied to claim the DTC, broken down by basic activities of daily living (BADL); (b) what is the total number and percentage of approved DTC claims, broken down by BADL; (c) what is value of DTC claims broken down by BADL; (d) what is the number and percentage of new applications processed and accepted, broken down by BADL, and how many of those approved (i) had eligibility for the DTC for five years or more, (ii) expired after a certain number of years; (e) what is the number and percentage of new applications processed and rejected, broken down by BADL; (f) what was, or is, the total budget for all OTC-related operations; (g) what was, or is, the total employee count for all OTC-related operations, and what is the number of medical practitioners working on the DTC; (h) how many days, on average, did the Canada Revenue Agency (CRA) take to assign a DTC application for review from the time of filing by the applicant; (i) how many days, on average, did the CRA take to mail (electronic or otherwise) a notice of determination related to a DTC application; (j) how many letters or correspondences did CRA send to the relevant medical practitioners asking for more information related to DTC applications received; (k) how many DTC applicants that were rejected or denied (i) requested a review of their application, (ii) challenged the CRA's decision by filing an income tax objection, (iii) moved beyond the CRA to an appeal filed to the Tax Court of Canada; (I) how long does the CRA take to review an application as noted in (k), (i) how many of those reviews resulted in an application being accepted; and (m) does the CRA have a dedicated telephone or TTY line for DTC applications, and (i) if so, how many calls has it received, (ii) if not, why not?

Q-2679² — May 3, 2024 — — With regard to the Select Luxury Items Tax (luxury tax) that came into effect on September 1, 2022: (a) what is the number of (i) aircrafts, (ii) vehicles, (iii) vessels, that were reported under the luxury tax, broken down by province and territory; (b) how many applications, registrations, forms, returns, and other documentation does the Canada Revenue Agency (CRA) have associated with the luxury tax, including those seeking exemptions, for taxpayers, including the full title of each piece of documentation; (c) what has been the total cost to the CRA to implement and administer the luxury tax to date; (d) what are the total amounts submitted to the CRA by taxpayers to date under (i) Part D, (ii) Part E, (iii) Part F, of Form B500; and (e) what are the total amounts submitted to the CRA by taxpayers to date under (i) Part D, (ii) Part E, (iii) Part F, of Form B501?

Q-2680² — May 3, 2024 — — With regard to the Climate Action Incentive Fund (CAIF), broken down by province and year: how much money was returned through the CAIF’s Municipalities, Universities, Schools and Hospitals Retrofit stream, broken down by (i) municipality, (ii) university, (iii) school, (iv) hospital?

Q-2681² — May 3, 2024 — — With regard to federal infrastructure funding under the Investing in Canada Plan, since January 1, 2016, broken down by year: (a) how much money has been announced for projects located in (i) Census Metropolitan Areas (CMAs), (ii) Census Agglomerations (CAs), (iii) areas outside of CMAs or CAs; (b) how much money has been distributed for projects located in (i) CMAs, (ii) CAs, (iii) areas outside of CMAs or CAs; (c) what are the details of each project in (a) and (b), including the (i) name of the CMA the project is located in, if applicable, (ii) name of the CA the project is located in, if applicable, (iii) name of the region the project is located in, if applicable, (iv) project description, (v) amount of funding originally announced, (vi) amount of funding distributed to date, (vii) date the funding was transferred to the recipient, (viii) recipient of the funding, (ix) current status of the project, (x) original projected completion date for the project, (xi) actual completion date for the project, if applicable, (xii) current projected completion date for the project, (xiii) reason for the project delay, if applicable; and (d) of the funding announced for projects in (a), were any projects later cancelled, and, if so, what are the details of each, including the (i) name of the CMA the project is located in, if applicable, (ii) name of the CA the project is located in, if applicable, (iii) name of the region the project is located in, if applicable, (iv) project description, (v) amount of funding originally announced, (vi) amount of funding transferred to the recipient, (vii) date of the cancellation, (viii) reason for the cancellation?

Q-2682² — May 3, 2024 — — With regard to the M-KOPA project that received financing through the Development Finance Institute Canada (FinDev Canada), a Canadian Crown corporation that is a subsidiary of Export Development Canada (EDC): (a) what assessments has EDC made to ensure that M-KOPA is properly accounting for all expenditures of taxpayer funds provided by the Government of Canada; (b) has the government reviewed and analyzed any of the expenditures by M-KOPA through FinDev Canada and EDC, and, if so, what are the details of all written, electronic and other documents pertaining to M-KOPA and funds provided to this organization; (c) has any auditing been done of M-KOPA or of FinDev Canada in relation to M-KOPA, and, if so, what were the findings; (d) what was the timeline for the approval of investments made by the Government of Canada, through EDC to FinDev Canada then to M-KOPA; and (e) what are the details of all memorandums and briefing notes about M-KOPA, all financial and contractual details including all memorandums and briefing notes and scope documents and economic impact analysis as well as all other financial documents related to M-KOPA that were sent or received by EDC, FinDev Canada, or any relevant ministerial offices and ministers, deputy ministers, assistant deputy ministers, the Minister of Finance, the Prime Minister and the Office of the Prime Minister, the Privy Council Office, and any other outstanding documentation that discusses the provision of funding or potential funding and screening of M-KOPA from 2016 to 2024?

Q-2683² — May 3, 2024 — — With regard to the recently announced emissions cap on Canada's oil and gas sector: (a) what assessments has the Government of Canada made regarding the economic impact on Gross Domestic Product and Export amounts, by dollar, for Canada; (b) has the government analyzed and reviewed the potential impact to Canadian firms that export energy products, and, if so, what are the details; (c) has the government considered the potential economic fallout in terms of job losses across the energy sector, at the provincial and territorial level, and, if so, what were the findings; (d) prior to the announcement of the emissions cap, did the government engage in any public relations or briefings with non-government organizations (NGO), the United Nations, and any sub-directorates of the United Nations at the ministerial level, and, if so, what was the nature of those discussions and the result of those discussions; (e) did the government procure any NGO or outside-of-government entities or actors to raise the subject within the Canadian media sphere, and, if so, who was involved and how much money was spent on these endeavors; and (f) what are the financial and contractual details of all memorandums and briefing notes, scope documents and economic impact analysis about the emissions cap that were sent to, or received by, the Minister of Export Promotion, International Trade and Economic Development, the Minister of the Environment and Climate Change, and the Minister of Finance, as well as any relevant ministerial offices and other involved ministers, deputy ministers, assistant deputy ministers regarding the emissions cap policy file, from 2016 to 2024?

Q-2684² — May 3, 2024 — — With regard to the Canada Revenue Agency and write-offs of accounts receivable, broken down by fiscal year from 2015-16 to 2023-24: (a) what was the total amount of write-offs; (b) how many (i) individual taxpayers, (ii) corporations, had amounts written-off; (c) what was the average amount written-off for (i) individual taxpayers, (ii) corporations; (d) what was the dollar amount of the single largest write-off, broken down by the (i) Financial Administration Act, (ii) Bankruptcy and Insolvency Act, (iii) Income Tax Act, (iv) Excise Tax Act; and (e) what was the dollar amount of the single largest write-off for (i) an individual taxpayer, (ii) a corporation?

Q-2685² — May 3, 2024 — — With regard to the Treasury Board Secretariat (TBS) hybrid workforce model for the federal public service: (a) has the TBS ever sought the opinion of the Office of the Privacy Commissioner of Canada regarding the concern for and risk of privacy and data breaches of sensitive and confidential information of Canadian citizens that may be caused with malicious intent such as a cyberattack, accident, or negligence, and, if so, when was the opinion sought and what was the opinion; and (b) is the TBS aware of any privacy and data breaches that have occurred with federal workers operating off-site since March 16, 2020, as a result of working from home on unsecured networks, devices, software, or hardware, and, if so, what are the details of each breach including for each the (i) date, (ii) department or agency involved, (iii) summary of what occurred, (iv) number of individuals whose information was impacted, (v) type of information breached, (vi) length of time until the breach was resolved, (vii) details on if and how those whose information was breached were notified, (viii) date on which the Privacy Commissioner was notified, if applicable?

Q-2686² — May 3, 2024 — — With regard to the Known Traveller Digital Identity (KTDI) project announced by the government in January 2018 and the successor pilot on Digital Travel Credentials (DTCs): (a) what is the current status of both projects; (b) why was the decision made to not resume the KTDI; (c) how was the data, including personal data, that was obtained through the KTDI used; (d) was the data, including personal data, that was obtained through the KTDI retained, and, if so, by whom, including the country, territory, organization, and company details, including (i) which types of data were retained, (ii) where is the data stored; (e) what is the nature of the government's involvement, including its agencies, in the new DTC project; (f) what is the World Economic Forum’s involvement in the new project, if any; (g) who are the project partners; (h) what is the end date of the DTC project; (i) how many Canadian travellers opted into the project to date; (j) for travellers who have been participating in the project, what type of data was shared with (i) the government, (ii) third parties; (k) what third parties received the data in (j)(ii); (l) what specific technologies is the government testing, and what are the parameters around that testing; (m) what (i) benefits of, (ii) problems with, the technologies have been identified to date; and (n) what are the total government expenditures related to the KTDI and DTC projects since 2018, broken down by type of expenditure?

Q-2687² — May 3, 2024 — — With regard to government information on weather modification activities in Canada since 2015: (a) what weather modification activities is the government aware have taken place, including, but not limited to, cloud seeding or modification, hail suppression, fog dissipation, precipitation modification, lightning modification, hurricane seeding; (b) what are the (i) start and end dates of the activities in (a), (ii) stated objectives, (iii) geographic areas affected; (c) what techniques, chemicals and equipment are involved in each of the known weather modification activities; (d) is the government aware of any unlawful or disputed weather modification activities in Canada, and, if so, what are the details including the dates and summaries of each activity; (e) what, if any, government support or funding is provided to any of the activities in (a); (f) which government departments or agencies are involved in activities in (e), and what are the program objectives and research areas; (g) which, if any, international entities are involved in any of the activities; and (h) what outcomes and impacts have been observed by these activities and the methods and chemicals employed, including impacts on the environment, storm severity, and any other impacts?

Q-2688² — May 3, 2024 — — With regard to the Universal Broadband fund, broken down by year and province or territory: how much money did the fund disperse and how much money went to (i) Rogers, (ii) BCE, (iii) Telus, or its subsidiaries?

Q-2689² — May 3, 2024 — — With regard to the electoral district of Churchill—Keewatinook Aski, broken down by fiscal year since 2005-06: what are the details of all federal infrastructure investments, including direct transfers to municipalities, regional district associations or First Nations, national parks, highways, etc.?

Q-2690² — May 3, 2024 — — With regard to Canada’s participation in the World Economic Forum Annual Meeting in Davos, Switzerland, from January 15 to 19, 2024: (a) how many individuals were part of Canada’s delegation; (b) who were the members of the delegation, including, for each, their (i) name, (ii) title, (iii) role; (c) what are the details of all meetings held in Davos involving the Deputy Prime Minister, including, for each, the (i) date, (ii) names and titles of the attendees, (iii) purpose of the meeting, (iv) agenda items, (v) summary of what occurred at the meeting, including any agreements made; (d) what are the details of all meetings held in Davos involving members of the Canadian delegation other than the Deputy Prime Minister, including, for each, the (i) date, (ii) names and titles of the attendees, (iii) purpose of the meeting, (iv) agenda items, (v) summary of what occurred at the meeting, including anything that was agreed to; (e) what are the details, including the summary of terms, of any agreements entered into during the forum; (f) what are the details of all follow-up action taken by the government as a result of what happened at the forum; (g) what are the details of all memoranda or briefing notes prepared to support Canada’s delegation to the forum, including, for each, the (i) date, (ii) sender, (iii) recipient, (iv) title, (v) subject matter, (vi) summary of contents, (vii) file number; and (h) what was the total cost to the taxpayer, broken down by category of expense?

Q-2691² — May 3, 2024 — — With regard to the Canada Infrastructure Bank's (CIB) investment in the Avenue Living residential retrofits: (a) what is the summary of the terms of the project agreement with Avenue Living; (b) which properties are undergoing retrofits financed by the CIB; (c) at which properties is the CIB aware of significant rent increases since the financial close of the agreement; (d) how much of the investment has been disbursed to date and how has that financing been disbursed; (e) what is the current status of each of the retrofit projects at Avenue Living properties; (f) what measures did the CIB take when the investment agreement was made to ensure the investment would not be used as a rationale to increase rent; (g) if the answer to (f) is none, why were no measures taken; (h) what, if any, changes to the agreement will the CIB make in light of the rent increases at some properties; and (i) what changes is the CIB implementing to ensure its financing of retrofits do not result in rent increases at rental properties?

Q-2692² — May 3, 2024 — — With regard to Canada Revenu Agency registered charities: (a) which charities that had Israeli nationals as agents or intermediaries had their status revoked due to a failed audit between 2017 and 2023; (b) which charities that had Israeli nationals as agents or intermediaries failed audits between 2017 and 2023 and did not have their status revoked; (c) what are the internal rules, regulations, and protocols around revocation of charity status with regard to both domestic and international recipients; and (d) what are the CRA’s risk assessment tools, and the risk matrix surrounding charities with international intermediaries?

Q-2693² — May 3, 2024 — — With regard to the government response to Order Paper Question Q-2422 regarding the awarding of non-competitive contracts, for Export Development Canada and for Public Services and Procurement Canada, broken down by year, from 2016 to the present: for each contract, what is the (i) recipient’s total amount of the contract, (ii) reason, if any, for awarding the contract, (iii) name of the organization that received the contract?

Q-2694² — May 3, 2024 — — With regard to spending on consultants by the government, broken down by year since 2018, and by department or agency: what was the total spending on external consultants (professional and special services) that are not an employee of a Crown corporation, agent of the Crown, or another department of the Government of Canada?


¹ Requires Oral Answer ² Response requested within 45 days